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Abstract 
Purpose: To determine if bolus electron conformal therapy (BECT) combined with volumetric modulated 
arc therapy (VMAT) and flattening filter free volumetric modulated arc therapy (FFFVMAT (6x and 
10x)) can maintain equal or better dose coverage than standard volumetric modulated arc therapy 
(VMAT) while reducing doses to organs at risk (OARs). 
Methods: BECT+VMAT, FFFVMAT (6x and 10x), and VMAT treatment plans were produced for ten 
post-mastectomy radiotherapy (PMRT) patients previously treated at our clinic. The treatment plans were 
created on a commercially available treatment planning system (TPS) and all completed treatment plans 
were reviewed and approved by a radiation oncologist. The plans were evaluated based on planning target 
volume (PTV) coverage, tumor control probability (TCP), dose homogeneity index (DHI), conformity 
index (CI), dose to organs at risk (OARs), and second risks for OARs. 
Results: All techniques produced clinically acceptable PMRT plans. Overall, BECT+VMAT plans 
exhibited significantly higher maximum dose compared to all VMAT techniques. BECT+VMAT and 
FFFVMAT10x had slightly improved TCP over FFFVMAT6x and VMAT (p > 0.05). However, all 
VMAT techniques showed statistically significant improvement in CI and DHI over BECT+VMAT. All	
techniques	showed	no	statistical	significant	difference	in	mean	lung	dose. BECT+VMAT exhibited a 
reduced mean heart dose	over	VMAT (p = 0.06). FFFVMAT6x had significantly higher mean heart dose 
compared to VMAT. In	addition,	BECT+VMAT was able to reduce mean dose to the contralateral breast	
with	 statistical	 significance,	 compared	 to	 VMAT. Both FFFVMAT techniques had comparable but 
slightly reduced dose compared to VMAT with FFFVMAT6x showing statistical significance. 
Conclusion: This work has shown that BECT+VMAT produces clinically acceptable plans while 
reducing OARs doses. Both FFFVMAT techniques are comparable to VMAT with FFFVMAT6x having 
slight improvements. In addition, FFFVMAT techniques exhibited reduced treatment times over VMAT. 
Even though all VMAT techniques produce more homogenous and conformal dose distributions, 
BECT+VMAT is a viable option for treating post-mastectomy patients. This work has demonstrated that 
xiv 
patients with increased risk of cardiovascular disease or radiation-induced cancer of the contralateral 
breast may benefit from BECT+VMAT. Also, patients with increased risk of radiation-induced cancer of 
the contralateral breast may benefit from FFFVMAT6x. 
1 
Chapter 1  Introduction 
1.1 Background and Significance 
Breast cancer is the second leading cause of cancer related deaths among women preceded only 
by lung cancer (Siegel et al., 2015). Breast cancer is estimated to have the highest incidence rate of all 
cancers among women in the United States in the year 2015 (Siegel et al., 2015). As shown in figure 1.1, 
it is estimated in 2015 that 29% (231,840) of new cancer cases will be breast cancer and 15% (40,290) of 
cancer related deaths among women will be attributed to breast cancer.  
   
Figure 1.1 Leading Cancer types for estimated new cases and deaths for 2015. Source: Siegel et al., 
(2015) 
 
In general there are three major techniques to treat breast cancer: surgery, chemotherapy, and 
radiation therapy. Surgery and radiation therapy treat local and regional disease while chemotherapy is a 
systemic treatment. Early stage disease can be treated with breast conserving surgery called a 
2 
lumpectomy or a mastectomy in conjunction with postoperative radiotherapy and systemic chemotherapy 
(Harris et al., 1996, Bonadonna et al., 1997, Wood et al., 2005). Disease with a large tumor of greater 
than 5 cm or multicentric disease will usually require a mastectomy (Overgaard et al., 1997).  
There are three types of mastectomies. A simple mastectomy is the removal of the breast tissue 
alone. A modified radical mastectomy includes the removal of the breast tissue and axillary lymph nodes. 
A radical mastectomy is the same as a modified radical mastectomy with the additional removal of the 
underlying pectoralis major muscle. With advanced disease, in addition to the mastectomy, post-
mastectomy radiotherapy (PMRT) is usually indicated (Harris et al., 1996, Bonadonna et al., 1997, Wood 
et al., 2005). 
1.2 Post-Mastectomy Radiotherapy (PMRT) 
More advanced disease that has axillary lymph node involvement and positive surgical margins 
will usually require PMRT (Overgaard et al., 1997). PMRT can potentially prevent local recurrence that 
could be caused by microscopic disease left behind after surgery (EBCTCG, 2005). Several studies have 
shown that PMRT improves local control of primary tumor and increases overall long term survival of 
breast cancer patients (Overgaard et al., 1997, Peirce et al., 2002, EBCTCG, 2005, Marks et al., 2010, 
Taddei et al., 2013, Fischbach et al., 2013, Ma et al., 2013, Zhang et al., 2015). Overgaard et al. (1997) 
shows the estimated ten year overall survival of 1708 women who were treated with concurrent 
radiotherapy and chemotherapy (852) and those treated with chemotherapy alone (856), the overall 
survival at 10 years is improved by nearly 10% with the use of radiotherapy. In addition, another study by 
the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) estimated an approximate 5.4% 
reduction in breast cancer mortality among 8505 women who underwent mastectomy plus radiotherapy 
versus mastectomy alone (EBCTCG, 2005). Overgaard et al. (1997) determined that no specific 
subgroups of women benefited more from PMRT. There are several radiation delivery treatment 
technologies available. However, currently there is no “gold standard” for post-mastectomy chest wall 
irradiation (Peirce et al., 2002, Fischbach et al., 2013). 
3 
Post-mastectomy chest wall treatment fields typically include the chest wall, internal mammary 
chain lymph nodes (IMN), axillary lymph nodes (AX), and the supraclavicular lymph nodes (SC) (van 
der Laan et al., 2010, Nichols, 2012, Hernandez, 2014). The Radiation Therapy Oncology Group (RTOG) 
further defines the area for treatment (RTOG, 2015). Figure 1.2 is a beams eye view of the treatment area 
for a typical post-mastectomy treatment area (Hernandez, 2014). The area covers the chest wall with the 
superior border covering the SC nodes, the medial border covers the IMN, the inferior border matches the 
apparent loss (no longer see the inferior border) of the contralateral breast, and the lateral border runs to 
the mid-axillary line. In addition, the anterior border of the treatment volume is the skin surface and the 
posterior border is the rib-pleural interface including the ribs and muscles (RTOG, 2015). It is important 
to increase the skin dose to adequate levels. For treatments using 6 MV photons a uniform tissue-
equivalent material called bolus is used to increase the skin dose in the “build-up” region of the photon 
beam (Fischbach et al., 2013, Hernandez, 2014). A Bolus can be seen on the patient’s surface in Figure 
1.2.  
Figure 1.2 Beams eye view of typical post-mastectomy treatment field. SC: supraclavicular lymph nodes; 
AX: axillary lymph nodes; CW: chest wall; IMN: internal mammary chain lymph nodes. Source: 
Hernandez (2014) 
 
1.3 PMRT Techniques 
Historically PMRT has been delivered using a mixed-beam (MB) technique. One method utilizes 
tangential photon beams for the chest wall with an anterior electron beam for regional lymph nodes 
(Peirce et al., 2002, Ma et al., 2013). Another method uses anterior and posterior photon fields to treat the 
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supraclavicular and axillary lymph nodes with anterior and oblique electron fields to treat the chest wall 
(Overgaard et al., 1997, Nichols, 2012).  
Beyond traditional treatment methods, there are advanced technologies for PMRT: Intensity 
Modulated Radiation Therapy (IMRT) has been shown to improve target dose homogeneity and 
conformity in addition to spare normal tissues over conventional methods (Rudat et al., 2014, Zhang et 
al., 2015). At Mary Bird Perkins Cancer Center (MBPCC) in Baton Rouge Louisiana the primary 
methods for PMRT are Helical Tomotherapy and Standard Volumetric Modulated Arc Therapy (VMAT) 
(Nichols, 2012), two types of advanced IMRT. VMAT is a method of delivering IMRT in a continuous 
arc and has been shown to conform well and deliver quality treatments to the chest wall (Nichols, 2012, 
Zhang et al., 2015). Zhang et al. (2015) has shown that VMAT plans exhibit an improvement over 
conventional IMRT plans in sparing healthy tissue for PMRT. Figure 1.3 shows isodose distributions 
from IMRT and VMAT plans for a left side post-mastectomy chest wall patient; VMAT delivered less 
low-dose to the heart, left lung, and less high-dose to the contralateral breast. Figure 1.4 shows the Dose 
Volume Histogram (DVH), for the same patient, giving a graphical representation of the reduced doses in 
the heart, left lung, and contralateral breast. In addition, VMAT is able to reduce the number of monitor 
units (MU) required, resulting in shorter treatment times and less whole body dose compared with IMRT 
(Zhang et al., 2015). 
Figure 1.3 Isodose comparisons between IMRT and VMAT for PMRT. Source: Zhang et al., (2015) 
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Figure 1.4 DVH comparison between IMRT and VMAT for PMRT plans shown in figure 1.3. IMRT 
displayed as solid line and VMAT as dashed line. Taken from Zhang et al., (2015) 
 
1.4 Flattening Filter Free VMAT (FFFVMAT) 
Helical Tomotherapy (HT) and Cyberknife utilize unflattened photon beams (Georg et al., 2011) 
and many VMAT linear accelerators have the flattening filter free option. Historically, conventional 
photon beams are flattened using a flattening filter (a Gaussian shaped high-Z material used to spread out 
the forward peak of the unflattened beam) (Zwahlen et al., 2012). This was done to achieve a flat, 
uniform beam that resulted in simplified calculations and easier treatment planning for IMRT treatments 
(Cashmore et al., 2008, Zwahlen et al., 2012). In contrast, unflattened beams that do not use a flattening 
filter are forward peaked (Cashmore et al., 2008). It has been stated that for treatments requiring highly 
modulated photon fields the flattened beam is unnecessary since the goal is a non-uniform field (Mackie 
et al., Georg et al., 2011) and it has been shown that flattened and unflattened optimized photon fluence 
maps are similar for IMRT and VMAT (Zwahlen et al., 2012). Figure 1.5 compares the normalized 
measured percent depth dose (PDD) data for the flattened and unflattened 6 MV beam for one of the 
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linear accelerators at MBPCC. The two beams are very similar with only slight differences in the build-up 
region, depth of maximum dose (dmax), and less than five percent difference in the low dose tail of the 
curve. The dmax for the flattened beam is 1.67 cm and dmax for the unflattened beam is 1.78 cm, a 1.1 mm 
difference that is in agreement with other institutions (Georg et al., 2011).  
Unflattened photon beams exhibit many benefits over traditional flattened beams. Cashmore et al. 
(2008) reported several dosimetric benefits of unflattened photon beams, including reduced penumbra, 
lower out-of-field dose, increased dose rate, and reduced head scatter (Cashmore et al., 2008). One of the 
major advantages of flattening filter free machines is the reported reduction in head scatter. Cashmore et 
al. (2008) showed a reduction in head scatter by up to 70%. This can reduce out-of-field dose and may be 
more pronounced for large field sizes such as those used for post-mastectomy chest wall treatments 
(Cashmore et al., 2008, Zwahlen et al., 2012). Figure 1.6 shows reduced head scatter, normalized to a 10 
x 10 cm2 field, for large field sizes for 6 MV photon beam.  
Figure 1.7 shows the normalized x-axis cross-plane profiles for the flattened and unflattened 6 
MV beam for one of the linear accelerators at MBPCC. The figure shows a reduction in out-of-field 
relative dose. Also seen is the forward peak and the flattened peak of the unflattened and flattened beams, 
respectively. Another benefit of flattening filter free beams is an increase in delivery efficiency resulting 
in increased dose rates (Mackie et al., Cashmore et al., 2008, Sorensen et al., 2011, Zwahlen et al., 2012, 
Lang et al., 2013, Spruijt et al., 2013,). This can reduce the delivery time of treatments but is dependent 
on physical machine constraints such as Multi-Leaf Collimator (MLC) speed and gantry rotation speed 
(Lang et al., 2013). In addition, studies have shown that increased dose rates will have no influence over 
treatment outcomes (cell survival) compared to lower dose rates seen with flattened beams (Sorensen et 
al., 2011).  
 Flattening filter free beams have softer energy spectra. This is because the flattening filter will 
preferentially attenuate low energy photons causing beam hardening. The result of a softer beam is 
increased skin dose (Mackie et al., Georg et al., 2011). Furthermore, removing the flattening filter could 
increase the dose accuracy of the treatment planning system (Cashmore et al., 2008, Georg et al., 2011). 
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It has also been shown that the dose conformity and dose homogeneity in the patient is similar for both 
flattened and unflattened photon beams (Zwahlen et al., 2012, Spruijt et al., 2013).  
 
Figure 1.5 Normalized PDD data for 6 MV photon beam from one of the linear accelerators at Mary Bird 
Perkins Cancer Center Baton Rouge Louisiana. 
















Figure 1.6 Head scatter factor as a function of field size for 6 MV photon beam (normalized to a 10 x 10 
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Figure 1.7 Normalized x-axis cross-plane profile for flattened and unflattened 6 MV photon beam from 
one of the linear accelerators at Mary Bird Perkins Cancer Center. 
 
1.5 BECT+IMXT 
Another method for treating post-mastectomy chest wall is mixed beam therapy consisting of 
bolus electron conformal therapy (BECT) combined with intensity modulated x-ray therapy (IMXT). 
High-energy electrons have a short range in tissue. This allows electron therapy to have rapid distal dose 
fall-off and therefore conforms to the distal edge of the target (Mu et al., 2004, Hogstrom et al., 2008). 
These characteristics make electrons suitable for the treatment of the chest wall where the target volume 
is superficial and organs at risk (OARs) like the lungs and heart are close to the target (van der Laan et 
al., 2010, Rosca, 2012). Advanced electron therapy uses energy modulation to further control the distal 
dose fall-off (Hogstrom et al., 2008). One method of achieving energy modulation for electron beams is 
the use of wax bolus on the patient surface where the distal edge is machined to achieve an excellent fit to 
the patients chest wall and the proximal edge is machined with a variable surface to achieve 90% isodose 
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coverage while conforming to the planning target volume (PTV), sparing distal OARs (Hogstrom et al., 
2008, Rosca, 2012). In addition to providing a conformal dose distribution, BECT sometimes improves 
dose homogeneity by smoothing patient surface irregularities. BECT has been shown to be very effective 
at treating post-mastectomy patients (Perkins et al., 2001, Hogstrom et al., 2008, Kavanaugh et al., 2013). 
A machineable wax bolus used in Bolus –ECT is shown in figure 1.8. Dose homogeneity can still be a 
problem and can be clinically unacceptable. However, optimizing IMXT over a BECT dose plan in mixed 
beam therapy can improve dose homogeneity to the PTV (Hogstrom et al., 2008, Kavanaugh et al., 
2013). Another important advantage to mixed beam therapy over IMXT alone is reduced normal tissue 
integral dose that has an important effect on reducing side effects of the treatment (Mu et al., 2004, van 
der Laan et al., 2010, Rosca, 2012, Kavanaugh et al., 2013). Figure 1.9 compares IMXT and BECT alone 
to the mixed-beam treatment plan. It shows that the mixed-beam has more uniform dose to the PTV than 
BECT alone and less normal tissue integral dose than IMXT alone. Figure 1.10 reveals the reduced 
normal tissue integral dose that can be achieved with mixed-beam therapy of electrons and IMXT as 
compared to IMXT only. 
 
Figure 1.8 Machineable wax bolus on patient surface used in BECT. Source: Perkins et al., (2001) 
10 
         
Figure 1.9 Treatment plan comparison of IMXT (a), BECT (b), and mixed beam therapy (c). Source: 
Kavanaugh (2013) 
 
                           
Figure 1.10 Treatment plan comparison of BECT+IMXT (above) and IMXT alone (below). Source: van 





1.6 PMRT Complications 
Side effects, including normal tissue complications such as second cancers, are serious concerns 
with all radiotherapy. It is especially important for young women to reduce contralateral breast dose to 
reduce the risk of secondary cancer associated with conventional post-mastectomy radiotherapy methods 
(van der Laan et al., 2010, Spruijt et al., 2013, Zhang et al., 2015). Research has shown breast irradiation 
is linked to increased side effects of the skin, heart, and lung (Levitt & Perez, 1987, Harris et al., 1996, 
Lichter, 1998, Almberg et al., 2011, Donovan et al., 2012, Rudat et al., 2014). Risk models such as the 
biological effects of ionizing radiation (BEIR) VII risk model, lifetime attributable risk (LAR), linear 
quadratic (LQ) model, and other normal tissue complication probability (NTCP) models and second 
cancer complication probability (SCCP) models are available to researchers and clinicians but care must 
be taken in using them and they should not be used for clinical decision making rather a tool for 
comparing techniques. (Peirce et al., 2002, Marks et al., 2010, Donovan et al., 2012). Quantitative 
Analysis of Normal Tissue Effects in the Clinic (QUANTEC) guidelines are used to define the limiting 
dose to healthy tissue to reduce the likelihood of serious side effects (Marks et al., 2010).  These tools are 
very useful when comparing different modalities for treating post-mastectomy patients.  
1.7 Purpose of Study/Statement of Problem 
With all of the knowledge and experience available today, there are still gaps in knowledge that 
need to be filled. Advanced methods are controversial as to whether they improve tumor control and 
reduce side effects. More treatment planning studies need to be conducted using flattening filter free 
beams with large field sizes such as those used in post-mastectomy radiotherapy (Cashmore et al., 2008, 
Spruijt et al., 2013). In addition, more comparative studies looking at treatment plan quality for flattening 
filter free beams are needed (Georg et al., 2011). Reports on conformal electron therapy planning are 
limited and need to be increased (van der Laan et al., 2010). It has also been reported that current 
commercial TPS do not calculate out-of-field dose and skin dose accurately (Almberg et al., 2011, 
Donovan et al., 2012, Zwahlen et al., 2012). Anthropomorphic phantom measurements are needed for 
verifying TPS calculation accuracies and for more robust side effect calculations (Almberg et al., 2011, 
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Donovan et al., 2012). Currently no studies have been conducted using FFFVMAT or BECT+VMAT for 
left-side PMRT. This study was conducted to determine if bolus electron conformal therapy (BECT) 
combined with volumetric modulated arc therapy (VMAT) and FFFVMAT (6x and 10x) can maintain 
equal or better dose coverage than VMAT while reducing doses to OARs. 
1.8 Hypothesis and Specific Aims 
For a sample of left-sided post-mastectomy breast cancer patients, BECT+VMAT and 
FFFVMAT (6x and 10x) can maintain equal or better dose coverage than VMAT while statistically 
significantly lowering (p < 0.05) predicted risks of side effects. 
This hypothesis was tested by comparing calculated dosimetric and radiobiological endpoints for 
ten randomly selected patients who have undergone VMAT treatment for the left side of the chest wall. 
Comprehensive dose reconstructions, tumor control probability, normal tissue complication probability 
for the whole heart, myocardium, lungs, and the second cancer risks for contralateral breast and lungs 
were performed. These tests were accomplished through the following specific aims: 
Aim 1: Compare treatment plans and predicted risks of side effects between BECT+VMAT and 
VMAT plans. 
Aim 2: Compare treatment plans and predicted risks of side effects between FFFVMAT (6x and 
10x) and VMAT plans. 
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Chapter 2  Methods 
2.1 Patient Selection 
 This study retrospectively considered ten consecutively sampled left side post-mastectomy 
patients. Table 2.1 lists the patient selection criteria. 
Table 2.1 Patient selection criteria 
Patient and Treatment 
Factors Inclusion Criteria Exclusion Criteria 
Age 20yrs<age<80yrs Age<20yrs, Age>80yrs 
Surgery Mastectomy Bi-lateral Mastectomy, Lumpectomy, Chemo Port 
Disease Localized to chest wall and regional lymphatics Distant metastases 
Treatment VMAT, 1 or 2 arcs Other 
 
 All patients received a left side modified radical mastectomy and were treated by the same 
radiation oncologist at MBPCC. All CT data sets were anonymized and assigned a unique research 
identifier ranging from CW1 to CW10. BECT+VMAT, VMAT (6x), and FFFVMAT (6x and 10x) 
treatment plans were produced on pre-contoured and clinically used computed tomography (CT) scans. 
CT scans had been acquired on a large bore GE LightSpeed 16 CT scanner (General Electric Medical 
Systems). For all ten patients, new VMAT and FFFVMAT (6x and 10x) treatment plans were produced. 
For nine of the patients, BECT+VMAT plans were produced. The tenth patient was not used for 
BECT+VMAT because the PTV extended to the rib-lung interface and was therefor deemed unsuitable 
for BECT+VMAT. The treatment planning for all modalities were produced on a commercially available 
TPS in the clinical dosimetry lab at MBPCC. All completed treatment plans were reviewed and approved 
by a single board certified radiation oncologist (Dr. M. Sanders). Furthermore, the Louisiana State 




 All patients were previously scanned in the supine position with the free breathing CT data sets 
including all anatomy from the top of the head down to the lower abdomen. The PTV for each patient was 
previously contoured by the same radiation oncologist and was included in the anonymized data sets. The 
PTV included the chest wall, supraclavicular lymph nodes, axillary lymph nodes, and internal mammary 
chain lymph nodes, as shown in figure 1.2. Nine patient PTVs excluded RTOG specification for including 
ribs and intercostal tissue. In addition, patients had a 1 cm tissue-equivalent bolus placed on the surface of 
their chest wall. For this study the dose within the tissue-equivalent bolus was unnecessary so it was 
removed from the “PTV evaluate” contour used in optimizing and evaluating the plans.  
 Figure 2.1 shows the contours used in optimizing and evaluating the PTV in the treatment 
planning system. The green plus red is the original contour created by the radiation oncologist. The red 
contour is the modified “PTV evaluate” that does not include the 1 cm tissue-equivalent bolus. This 
contour was used in planning and optimizing all the VMAT techniques in this study. The red contour was 
also used for evaluating the PTV dose metrics for all techniques. The yellow contour is a 5 mm shell that 
is used to evaluate the skin dose within the PTV.  
 
Figure 2.1 Planning target volumes for all VMAT techniques and BECT+VMAT (red), including the 
chest wall and 1 cm tissue-equivalent bolus (red + green), and 5 mm skin contour (yellow) 
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 Figure 2.2 gives a three-dimensional representation of the PTVs used in planning and evaluating 
all techniques in this study. The image on the left shows the superclavicular PTV and electron chest wall 
PTV for the BECT+VMAT technique while the image on the right shows the PTV used for all the VMAT 
techniques as well as the VMAT component of the BECT technique. 
Figure 2.2 Planning target volumes with prescriptions for all VMAT techniques and BECT+VMAT.  
 
The organs at risk (OARs) were also included in the CT data sets and were drawn by the planning 
radiation oncologist for all the patients. The OARs included lungs, whole heart, contralateral breast, 
esophagus, trachea, and spinal cord. New contours were added to the original CT data sets which included 
a 0.8 cm ring around the PTV, used to control hot or cold spots around the PTV, an external skin contour 
used in BECT+VMAT planning, the 5 mm thick shell for evaluating the skin dose inside the PTV, and 
unspecified tissue which included everything inside the external skin contour excluding the above 
mentioned OARs. In addition, the contour for the myocardium was created following the method of 





Electron and SC component 
of BECT+VMAT PTV 
Rx = 40 Gy in 20 fx 
1. VMAT (all) PTV 
Rx = 50 Gy in 25 fx 
2. VMAT Component of  
            BECT+VMAT PTV 
 Rx = 10 Gy in 5 fx 
3. Evaluation PTV for all 
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2.3 VMAT Treatment Planning 
 Both VMAT (6x) and FFFVMAT (6x and 10x) treatment plans were created in Phillips Pinnacle3 
v9.8 treatment planning software (TPS). All VMAT treatment plans used commissioned beam data from 
MBPCC Elekta Versa HD linear accelerator using a prescribed dose of 50.0 Gy in 25 fractions. All plans 
used 0 degree couch angle and 45 degree collimator angle.  Every technique was planned using its 
maximum dose rate: VMAT (6x) used 600 Monitor Units (MU) per minute, FFFVMAT6x used 1200 MU 
per minute, and FFFVMAT10x used 2000 MU per minute. All dose calculations were conducted using a 
dose grid resolution of 4 mm3. Each plan also utilized two partial arcs due to the complexity of the cases 
and close proximity to lungs, heart, and contralateral breast. Each arc covered approximately 220° with 
about 56 control points and 4° gantry spacing. The first arc was planned to be delivered counterclockwise 
with starting angles between 170-180° (floor to ceiling) and stopping angles between 304-320°. The 
second arc was planned to be delivered clockwise. Inverse planning for all VMAT techniques was done 
using the SmartArc optimization algorithm utilized by Pinnacle3 v9.8 TPS.  
 The VMAT plans were optimized using a four-run technique. The first run consisted of 75 
iterations of the SmartArc algorithm in addition to 25 iterations of the convolution dose algorithm with 
the primary focus on PTV coverage. All PTV optimization objectives were set to a weight of 100. The 
starting optimization objectives and constraints for all VMAT plans are shown in table 2.2. All of the 
following runs consisted of 35 iterations each of the SmartArc algorithm. For the second run the hotspots 
from the first run were contoured and an objective was added with max dose constraint set to 5200 cGy 
with a weight of 100. The hot spots were contoured by creating a contour from the 5350 cGy isodose line. 
For the third run the “PTV evaluate” region of interest (ROI) was uniformly contracted by 0.2 cm and 
labeled PTV min dose. This ROI was added to the optimizer and given a min dose objective of 5000 cGy 
with a weight of 100. In addition, hotspots from the second run were contoured and an objective was 
added with max dose constraint set to 5200 cGy with a weight of 100. For the fourth run the focus was set 
to reduce the dose to the heart, lung, and contralateral breast. At the beginning of the run the target doses 
were reduced by an amount that resulted in the objective value for that ROI to be around 0.005. The 
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objectives can be adjusted in real time as the optimizer is running. While the last run was being optimized 
the target doses of the aforementioned ROIs were adjusted to keep their objective value around 0.005.  
 For the FFFVMAT techniques, after the first run, the DVH did not meet the goals assigned in the 
optimizer. To fix this problem a “warm run” was done. Following each optimization the prescription was 
automatically changed from 100% normalization to the calculation point to monitor units per fraction. 
Resetting the prescription to 100% normalization to the calculation point and starting the optimizer from 
where it left off using 35 iterations would typically fix this. If the “PTV evaluate” still did not have the 
proper coverage, then a new ROI was created in the region of the “PTV evaluate” where the dose was too 
low. This ROI was then added to the optimizer and given a min dose of 5000 cGy with a weight of 100 
and the optimizer was run for 35 iterations. After the “PTV evaluate” DVH had the proper dose coverage 
the four-run technique was continued. 
Table 2.2 Starting VMAT optimization objectives and constraints 
ROI Type Target Dose [cGy] Volume [%] Weight 
PTV Evaluate Min DVH 5000 98 100 
PTV Evaluate Max Dose 5200 - 100 
Total Lung Max DVH 1500 15 1 
Total Lung Max DVH 1000 35 1 
Total Lung Max DVH 500 60 1 
Total Lung Max Dose 4500 - 1 
Heart Max DVH 1500 15 1 
Heart Max DVH 1000 30 1 
Heart Max Dose 4000 - 1 
Esophagus Max Dose 2000 - 1 
Airway Max Dose 2000 - 1 
Spinal Cord Max Dose 1000 - 1 
Contralateral 
Breast Max Dose 1500 - 1 
Ring Max Dose 5000 - 25 
Unspecified Tissue Max Dose 2800 - 1 
 
2.4 BECT+VMAT Treatment Planning 
 BECT+VMAT treatment plans were produced for nine of the ten patients using Phillips Pinnacle3 
v9.8 TPS. All BECT+VMAT treatment plans used commissioned beam data from MBPCC Elekta 
Infinity linear accelerator with Agility treatment head. BECT+VMAT is a mixed modality technique 
utilizing electrons, open field photon beams, and dual-arc VMAT using 6 MV photons. It uses a 4:1 ratio 
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where 20 of the 25 total fractions are an electron field to the chest wall and parallel opposed open 
anterior-posterior (AP) and open posterior-anterior (PA) photon beams to the superclavicular area. 
Generalizations of these two PTVs are shown in figure 2.2 in the left image. The final 5 of the 25 total 
fractions utilized a dual-arc VMAT technique, as described in section 2.3 of this chapter. The prescription 
dose of the electron and open photon fields were 40 Gy in 20 fractions and the dual-arc VMAT was 
prescribed to 10 Gy in 5 fractions.  The VMAT PTV for this technique as well as the PTV used for final 
evaluation is shown in the right image of figure 2.2. Before creating these plans the original CT data sets 
needed modified.  
 Prior to creating these treatment plans the original CT data set field-of-view (FOV) needed to be 
increased. The original CT data sets were acquired using a 50 cm FOV on the CT scanner. When the 
machineable wax bolus contour was created it often extends outside the image space of this FOV. If this 
happens the contour could not be exported from the creation software. This required the FOV of the CT 
image set to be increased to approximately 70 cm. This was achieved by adding 20 cm margin to the left 
lateral and anterior portion of the CT image data set. 
 The same contours are used as in all the VMAT plans with the addition of carefully contouring 
out the tissue equivalent bolus material that is in place in the original CT images. This was not used for 
the electron portion of this technique. Once the contour is created the density was overridden to air, i.e. 
0.001 gcm-3.  
 To create the machineable wax bolus used in this technique, plan information including PTV and 
external skin contour structure files, beam orientation, beam modifiers, energy, and source to surface 
distance (SSD) were exported to the .decimal p.d (.decimal, Inc., Sanford, FL) software. The “PTV 
evaluate” ROI was split in order to create the “superclavicular PTV” and “BECT PTV” as shown in the 
left image of figure 2.2. Each patient was analyzed to properly identify the lowest optimal electron energy 
to give adequate coverage of the “BECT PTV”. The goal was to have the 90% isodose line cover the 
distal edge of the “BECT PTV” using a single electron beam. The energies used were selected from 11 
MeV, 13 MeV, 16 MeV, and 20 MeV with R90 values of 3.5 cm, 4 cm, 5 cm, and 6 cm, respectively. 
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 Electron isocenter was placed on the central slice of the “BECT PTV”, 5 cm anterior to the 
patient surface, resulting in a pre-bolus SSD of 105 cm allowing for adequate electron applicator 
clearance. The electron isocenter was also located laterally from the “BECT PTV” patient midline edge to 
approximately place the point in the center of the “BECT PTV”. The gantry angle was chosen so the 
beam direction was perpendicular to patient surface on central axis (approximately 45°).  
An electron field (cutout) was also created to conform the lateral edges of the electron beam to the 
“BECT PTV” plus margin. The following parameters were adjusted using the beams-eye-view (BEV) 
projection. A 1 cm margin was added around the “BECT PTV” to ensure the PTV was inside the 
penumbra and received 90% of the given dose. The couch was adjusted so the beam at the superior border 
had a straight edge, which slightly diverged from the “superclavicular PTV”. This resulted in a non-zero 
couch angle. In addition, the cutout matched the superior border of the “BECT PTV” to reduce the 
penumbra from spilling into the “superclavicular PTV”. The collimator was adjusted so the medial jaw 
was parallel to the “BECT PTV” medial edge. This adjustment maximized the distance between the 
“BECT PTV” outer edge and the electron field’s (cutout) outer edge. The smallest electron applicator was 
selected that left a minimum (distance from outer edge of applicator edge to the electron’s field edge) of 
1-2 cm margin (applicator sizes were either 20x20 cm2 or 25x25 cm2). The dose was calculated using a 
dose grid resolution of 2 mm3. 
The finalized ROI structures and electron beam characteristics were exported from the TPS and 
transferred to the .decimal p.d planning computer using file transfer protocol (FTP). The plans were then 
imported into .decimal p.d planning software (v5.1.9) for bolus creation.  
Bolus creation began by selecting the beam energy and the “BECT PTV” and external skin ROI 
structures. The bolus was created using a series of bolus operators and parameters that resulted in the best 
90% isodose line coverage of the distal surface of the “BECT PTV”. Typically the operation sequence 
was create followed by smooth using default parameters for both. Once the bolus design was finalized its 
shape was transferred back to the TPS.  
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The digital bolus contour was imported into a copy of the original treatment plan in the TPS 
labeled “Bolus-ECT”. The density of the bolus contour was set to 0.92 g/cm3 (Low et al., 1995, 
Kavanaugh, 2013). The monitor units for the beam were set based on a calculation using the dose 
prescription, beam energy, applicator size, effecive rectangular field size, and SSD taken from the 
.decimal p.d planning software. MU’s were calculated to give the prescribed dose to 95% of the given 
dose. The dose distribution was calculated using the Pencil Beam Redifinition Algorithm (PBRA) in the 
.decimal p.d planning software and the Pencil Beam Algorithm in the Pinnacle TPS.  
Continuing the planning process required adding the AP/PA open photon fields to deliver dose to 
the “superclavicular PTV”. First, the density of the bolus contour was turned off and the tissue equivalent 
bolus material was turned back on to calculate the photon components of the treatment plan. Modification 
of the bolus density results in the deletion of the ECT dose distribution, a necessary component of the 
treatment plan.  Thus, the ECT dose distribution was recreated by copying the plan.Trial.binary file into a 
copy of the “Bolus-ECT’ plan labeled “Bolus-ECT with IMXT” using identical dose grid parameters. 
From here the photon components of the treatment plan were created.  
The AP/PA photon isocenter was placed on the inferior border of the superclavicular PTV at its 
medial border. The AP beam combined 6 MV photons and 15 MV photons so as to achieve adequate dose 
coverage to deep portions of the “superclavicular PTV”.  Due to the depth of the PTV a PA beam of 15 
MV was also required. A multi-Leaf collimator was used to block the inferior border of the PTV to 
minimize or remove any hot spots (> 52 Gy) due to abutting the electron and photon beams. In addition 
there was a 1 cm margin around the superior and lateral borders of the PTV for proper dose coverage. The 
beams were weighted in such a way to maximize the 40 Gy prescription dose coverage while minimizing 
dose to tissue outside the superclavicular PTV. The beam angles were chosen to reduce dose to the 
esophagus and trachea and were approximately 345°. After the BECT PTV and superclavicular PTV were 
covered by their 40 Gy prescription the VMAT component of the plan was applied. The VMAT planning 
technique was identical to that described in section 2.3 with the exception it was optimized on top of the 
existing dose distributions. 
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2.5 Plan Acceptance Criteria 
 The following criteria were met for each treatment plan to be considered clinically acceptable and 
therefore representative of an actual plan administered to a patient.  
1. Planning Target Volume (PTV) Coverage: 
The volume of the PTV receiving at least 95% of the prescribed dose is greater than or 
equal to 95% (VD95% ≥ 95%). 
2. Organs At Risk (OARs) limitations: 
The volume of lungs receiving at least 20 Gy is less than 20% (VD20Gy < 20%). The 
volume of heart receiving at least 22.5 Gy is less than 20% (VD22.5Gy < 20%). 
2.6 Treatment Plan Evaluation Metrics 
2.6.1 Planning Target Volume (PTV) 
 The following dose-volume treatment plan metrics were evaluated for all treatment plans: 
1. Dose Volume Histogram (DVH) for the PTV 
2. Minimum, Maximum, and Mean doses with standard deviation for the PTV 
3. The dose that 95% of the PTV volume receives (D95%) 
4. Volume of the PTV that receives 95% of the prescription dose (VD95%) 
5. Volume of the PTV that receives 107% of the prescription dose (VD107%) 
6. Percent volume receiving 110% of prescribed dose within the treated volume (TV-V110%) 
7. Dose Homogeneity Index (DHI)  
8. Conformity Index (CI) 






where Dmax is the dose to 2% of the PTV, Dmin is the dose to 98% of the PTV, and DRX is the prescription 
dose (Wu et al., 2003). A DHI value of zero is ideal and represents a homogenous dose to the entire PTV. 










where TVRI is the target volume receiving the reference dose (47.5 Gy), TV is the PTV, and VRI is the 
volume receiving reference isodose of 47.5 Gy (Van’t Riet et al., 1997). A CI value of close to unity 
means the dose conformed excellently to the target volume.  
 TV-V110% was calculated as described by Chen et al. (2010) and is the percent volume receiving 
110% of the prescribed dose (55 Gy) within the treated volume (TV) where the treated volume is the 
volume enclosed by the prescribed dose (50 Gy). It has been shown that TV-V110% > 5.13% is an indicator 
of radiation induced skin toxicity that results in moist desquamation (Chen et al., 2010). 
2.6.2 Organs at Risk (OARs) 
1. DVH for each OAR 
2. Minimum, Maximum, and Mean doses with standard deviation for each OAR 
3. Volume of lungs Receiving 5 Gy, 10 Gy, 20 Gy or more 
4. Volume of Heart Receiving 5 Gy, 10 Gy, 22.5 Gy, 30 Gy or more 
5. Volume of contralateral breast receiving 5 Gy or more 
The OARs of most importance to this study were the lungs, heart, contralateral breast, skin, 
esophagus, spinal cord, and unspecified tissue. Radiation pneumonitis is of clinical concern for patients 
undergoing chest wall irradiation. The volume of lung receiving at least 20 Gy was less than or equal to 
20% (V20Gy ≤ 20%), as this has been shown to be the clinical threshold for pneumonitis (Ares et al., 2010, 
Hernandez, 2014). In addition, the volume of lung receiving at least 5 Gy was less than or equal to 42% 
(V5Gy ≤ 42%), as any more is related to an increase in lung toxicity (Ares et al., 2010, Hernandez, 2014). 
Side effects to the heart are also concerning for chest wall irradiation. Doses to the heart above 30 Gy 
have been shown to increase cardiac mortality (Gagliardi et al., 1998, Hernandez, 2014). Also, a dose of 
22.5 Gy to the heart has been correlated to increased rates of reduced myocardial perfusion (Ares et al., 
2010, Hernandez, 2014).  
2.7 Radiobiological Metric Comparison 
2.7.1 Tumor Control Probability (TCP) 
 The most important task of radiation therapy is the ability to control the tumor. This project used 
the Webb and Brenner model to calculate the tumor control probability (TCP) (Brenner, 1993; Webb and 
Nahum, 1993). The model accounts for repopulation of the tumor cells. Unfortunately, α, β, and n values 
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are not reported for the chest wall. The next most appropriate values available for those variables are the 
ones used for whole breast and were used for this study following previous investigators (Nichols, 2012, 
Hernandez, 2014). Hernandez and Nichols determined the model for the overall TCP is the product of 





where TCPi, the tumor control probability for each sub-volume i , or 
𝑇𝐶𝑃! = 𝑒!!∙!"! , 
[2.4] 
where N is the number of initial clonogenic cells in the tumor. N is 
𝑁 = 𝑛𝑉, 
[2.5] 
where n is the tumor cell density and is taken as 1.0X107 cm-3 (Webb et al., 1993) and V is the volume of 
the PTV. SFi in equation [2.4] is the cell survival fraction and is predicted with the linear-quadratic model 
for cell survival and is given by 




where the constant α is the rate of lethal cell damage and the constant β is the rate of sublethal cell 
damage. Di is the dose per fraction to sub-volume i. G accounts for fractionation and the half-time for 










Table 2.3 Parameters used to calculate TCP. 
Parameter Value Source 
α 0.51 Gy-1 (Hernandez, 2014, 
Nichols, 2012) β 0.061 Gy-2 
G 0.04 x = 25 fractions 
 
2.7.2 Normal Tissue Complication Probability (NTCP) 
 Normal tissue complication probability of the lungs with radiation pneumonitis grade two or 
higher as an endpoint was calculated using the Lyman-Kutcher-Burman (LBK) model (Seppenwoolde et 

















TD50 is the total uniform dose given to the organ that results in 50% complication risk and m is the slope 
of the dose-response curve. The dose delivered to the lungs is inhomogeneous and the treatment plan 
differential DVH was reduced to an equivalent uniform dose (EUD) using equation [2.10] (Seppenwoolde 
et al., 2003, Hernandez, 2014). The EUD is the dose that will result in the same NTCP as the 









where Di is the dose per fraction to sub-volume i, vi is the volume irradiated with dose Di, vtot is the total 
lung volume, and n is the volume effect parameter. The parameters used to calculate NTCP for the lungs 
are listed in table 2.4. 
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Table 2.4 Parameters used to calculate NTCP, radiation pneumonitis for the lungs. 
Parameter Value Source 
m 0.37 (Seppenwoolde et al., 2003, 
Hernandez, 2014) n 0.99 TD50 30.8 Gy 
 
 NTCP was also calculated for the whole heart and myocardium with cardiac mortality as the 
endpoint using the relative seriality model ((Kallman et al., 1992)). The relative seriality model considers 
the mixture of serial-arrange and parallel-arrange functional subunits of the heart and is 







where n is the total number of sub-volumes in the differential dose volume histogram, s is the relative 
seriality of the organ, defined as the ratio of serial functional subunits to the total functional subunits, and 
vi is the fractional volume of the heart receiving dose Di in sub-volume i. P(Di) is the probability of cell 
death when irradiated to a dose Di and is 





where  𝛾 is the maximum relative slope of the dose-response curve and TD50 is the total uniform dose 
given to the organ that results in 50% complication risk. The parameters used to calculate NTCP for the 
whole heart and myocardium with a biological endpoint of cardiac mortality are given in table 2.5. 
Table 2.5 Parameters used to calculate NTCP for the whole heart and myocardium with a biological 
endpoint of cardiac mortality 
Structure Parameter Value Source 
Whole Heart 
TD50 52.3 Gy 










2.7.3 Second Cancer Complication Probability (SCCP) 
 When patients require radiation therapy it is important for long-term survival to determine their 
risk for second cancers. In this study, second cancer complication probability (SCCP) of the contralateral 
breast and lung using the Schneider model (Schneider et al., 2005, Nichols, 2012, Hernandez, 2014) was 
calculated as 
𝑆𝐶𝐶𝑃 = 𝐼𝑛!"#𝑂𝐸𝐷!"#, 
[2.13] 
where Inorg is the organ specific absolute cancer incidence in percent per gray and represent lifetime risk 
assuming a residual life expectancy of 50 years. Inorg was estimated using Japanese atomic bomb survival 
data (Hernandez, 2014). OEDorg is the organ equivalent dose given in gray. It represents an evenly 
distributed dose to the organ to a corresponding inhomogeneous dose that causes the same radiation-
induced cancer incidence. This study used the linear dose-response model given by equation [2.14] and 
the linear-exponential dose-response model given by equation [2.15] for the lung for the contralateral 















where vi is the volume receiving dose Di and is summed over all voxels of the organ of volume Vorg. The 
parameter α is the organ specific cell sterilization parameter. Table 2.6 contains the parameters that were 
used to calculate SCCP for the contralateral breast and lungs. 
Table 2.6 Parameters for calculating SCCP of the contralateral breast and lungs 
Organ α Inorg Source 
Breast 0.085 Gy-1 0.78 %·Gy-1 (Schneider et al., 2005, Nichols, 2012, Hernandez, 
2014) Lungs 0.085 Gy-1 1.68 %·Gy-1 
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2.8 Statistical Analysis 
 To test the hypothesis, the goals of specific aim 1 and 2 were to show that the prescribed dose 
coverage was not statistically significantly different for BECT+VMAT or FFFVMAT (6x and 10x) as 
compared to VMAT. Also, to show that the predicted risks of side effects were reduced by using 
BECT+VMAT or FFFVMAT (6x or 10x) with statistical significance as compared to VMAT. The mixed 
model approach (Guo et al., 2015) was performed for all the PTV treatment plan metrics to show no 
statistically significant difference between all modalities. In addition, the mixed model approach was 
performed for all the OARs treatment plan metrics, NTCP, and SCCP for all modalities. Our study 
consisted to 4 techniques of unequal sample size. The mixed model approach was required because there 
is missing data for BECT+VMAT (nine patients) as compared to the VMAT techniques (ten patients). 
The data was dependent on using the same patients and changing the treatment technique. In addition, the 
statistical analysis was based on parametric procedures and thus assumed normal distribution of the data. 
The mixed model approach first tested for significance between all four techniques. If significance was 
determined then a pairwise comparison was conducted (Guo et al., 2015).   
2.9 Obtain Out-Of-Field Dose Values Using Anthropomorphic Phantom Measurements 
 Studies have shown that treatment planning systems tend to underestimate out-of-field and skin 
doses (Almberg et al., 2011, Spruijt et al., 2013, Taddei et al., 2013, Jagetic & Newhauser, 2015). In this 
study anthropomorphic phantom measurements were conducted using thermoluminescent detectors 
(TLD) to correct for TPS calculation underestimates. An adult male phantom (CIRS, Model 701, Norfolk, 
Virginia) with a right breast attachment was used to simulate a left side mastectomy patient. The phantom 
was CT scanned and treatment plans were produced for VMAT, FFFVMAT (6x and 10x), and 
BECT+VMAT. In addition, a TLD location map was created to optimize TLD placement within the 
phantom.  
Measurements were conducted using TLD100 powder placed into powder holding rods. Each 
modality was delivered and measured with the exception of the electron component of BECT+VMAT. 
The measured TLD values were used to correct the DVHs used to calculated NTCP and SCCP for OARs 
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based on the method described by Howell et al. (2010). For example, the TPS calculated dose values 
below 5% in the DVH for an OAR were increased by a factor of measured dose per calculated dose. This 
resulted in increased dose values for TPS calculated doses from 0 Gy to 2.5 Gy which improved the 
accuracy of NTCP and SCCP predictions. More details of out-of-field dose measurements will be 
provided in a separate study (Yoon et al., in preparation). 
2.10 Treatment Time and Total Number of Monitor Units (MU) 
The time was measured for each treatment delivered to the CIRS phantom using a stopwatch for 
the VMAT and FFFVMAT plans. The treatment times were measured for 4 fractions (fx) for delivery of 
Arc 1 (beam on time), Arc 2 (beam on time), and total treatment time. Total treatment time includes 
delivery of both arcs in addition to the time in between arcs, time required to manually select and start the 
second arc. This time measurement was used to investigate reduced treatment time for FFFVMAT over 
VMAT. In addition, the total number of monitor units (MU) was recorded from the TPS for each 
technique.  
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Chapter 3 Results  
3.1 Patient CW4 
Patient CW4 has been chosen to be the representative patient for the cohort of patients used in 
this study. CW4 exhibits many, but not all, dosimetric and radiobiological findings close to the mean for 
the entire sample of patients. Patient CW4 was a 42 year old woman diagnosed with infiltrating ductal 
carcinoma of the left breast. The patient underwent post-mastectomy radiotherapy of the chest wall and 
regional lymph nodes following a modified radical mastectomy of the left breast at Mary Bird Perkins 
Cancer Center.  The results for patient CW4 will be shown in the following manner: 
1. Isodose distribution comparison 
2. Dose volume histogram comparison 
3. Dosimetric and radiobiological results for the planning target volume 
4. Dosimetric and radiobiological results for the lungs, heart, contralateral breast, and skin 
3.1.1 Isodose Distribution Comparison 
 Isodose distribution for patient CW4 for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT treatment plans in axial slice on VMAT beam isocenter are presented in figure 3.1. 
VMAT, FFFVMAT6x, FFFVMAT10x, and BECT+VMAT are shown in the top image, top middle 
image, bottom middle image, and bottom image, respectively. Table 3.1 lists the color coding used for 
isodose distributions in the following figures.  
Table 3.1 Color coding for isodose distributions 












 All VMAT techniques met the plan evaluation criterion that 95% of the PTV volume received at 
least 95% of the prescribed dose (47.5 Gy). The BECT+VMAT plan was just under the requirement with 
95% of the PTV volume receiving 94.8% of the prescribed dose (47.4 Gy). In addition, all techniques met 
the requirement that 20% of the lung volume received less than 20 Gy and 20% of the heart volume 
received less than 22.5 Gy. All of the VMAT techniques exhibited similar dose conformity and 
homogeneity. The BECT+VMAT plan showed less conformity and homogeneity than the VMAT plans. 
The BECT+VMAT plan showed reduced OARs doses with the largest reduction in dose to the 
contralateral breast and some reduction in the heart. In addition, FFFVMAT10x showed a slight reduction 
in dose to the contralateral breast compared to other VMAT techniques. The volume of the low dose 
regions (< 5 Gy) of the BECT+VMAT plan was reduced over all VMAT techniques. The BECT+VMAT 
plan showed the highest maximum dose as compared to any of the VMAT plans. This is especially 
apparent in the lateral portion of the PTV at the beam abutment region of the electron field and the open 
AP/PA photon fields. In addition, any region of the machineable wax bolus that has a steep or sharp edge 
caused hot and cold spots down stream in the patient. Smoothing the machineable wax bolus alleviated 
some of the hot spots but not all could be removed. This region showed hot spots on the order of 105% of 
the prescribed dose (52.5 Gy) and going up, in very small areas, as high as nearly 60 Gy.  
3.1.2 DVH Comparison 
 Figure 3.2 – 3.4 shows the cumulative dose volume histograms for patient CW4 comparing all 
techniques. The figures include the DVH for the PTV, lungs, heart, and contralateral breast. 
 Important regions in the PTV dose volume histogram (DVH) are the “shoulder” and the “fall-off” 
region. The shoulder describes the area of the DVH where the dose begins to bend away from 100% of 
the PTV volume. The fall-off region describes vertical part of the PTV curve around the prescription dose 
from 100% of the PTV volume to 0% of the PTV volume. The ideal PTV DVH would have a horizontal 
line from 0 Gy to prescription dose (50 Gy) at 100% volume with no shoulder and the fall-off region 
would be a vertical line at prescription dose from 100% volume to 0% volume. On the other hand, the 
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ideal OAR DVH would have a vertical line at 0 Gy from 100% volume to 0% volume and then horizontal 
at 0% volume or simply a point at (0,0).  
 Figure 3.2 plots the DVHs for BECT+VMAT and VMAT for patient CW4. For VMAT the DVH 
curve for the PTV has a fairly narrow shoulder with sharp distal fall-off, representing a uniform dose 
distribution. In contrast, for BECT+VMAT the DVH curve for the PTV has a wider shoulder with less 
sharp distal fall-off, representing a less homogenous dose distribution and a higher maximum dose as 
stated earlier. However, the reviewing radiation oncologist deemed the BECT DVH curve for the PTV to 
be clinically acceptable. 
 The BECT+VMAT plan showed a marginal reduction in lung dose over VMAT. The low dose 
and high dose regions between the two plans were similar with the greatest improvement between 5 Gy 
and 30 Gy. VMAT showed higher doses for the heart where BECT+VMAT had reduced doses in the 
higher dose regions. The mean heart dose was reduced from 9.2 Gy for the VMAT plan to 6.7 Gy for the 
BECT+VMAT plan. In addition the BECT+VMAT was able to reduce low dose for the contralateral 
breast over VMAT.  
 Figure 3.3 shows the DVH for FFFVMAT6x and VMAT for this patient. The DVH curve for the 
PTV is nearly identical for both techniques, with both showing a narrow shoulder and sharp distal dose 
fall-off. The OARs show very similar curves for both techniques. FFFVMAT6x actually shows slight 
increases in dose for both the lungs and heart in the high dose regions. However, FFFVMAT6x does 
show a slight decrease in high dose for the contralateral breast. Figure 3.4 shows the DVH for 
FFFVMAT10x and VMAT for patient CW4. Again the DVH curve for the PTV is nearly identical for 
both techniques. Similar trends can be seen for the lungs and heart as seen for FFFVMAT6x. The lungs 
and heart have slight increase in dose in the higher dose regions. For FFFVMAT10x the contralateral 
breast dose is decreased along the entire dose range. Overall, both FFFVMAT (6x and 10x) techniques do 
not show improvements over the VMAT technique and in fact are slightly worse based on the treatment 


















































Figure 3.1 Isodose distribution for patient CW4 for VMAT (top), FFFVMAT6x (top middle), 































Figure 3.2 DVH for patient CW4 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 
























Figure 3.3 DVH for patient CW4 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 
for FFFVMAT6x (dashed line) and VMAT (solid line). 
- - - - - BECT+VMAT 
            VMAT 
- - - - - FFFVMAT6x 


























Figure 3.4 DVH for patient CW4 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 
for FFFVMAT10x (dashed line) and VMAT (solid line). 
 
3.1.3 PTV 
Table 3.2 gives the evaluation metrics for the PTV for patient CW4. All plans were normalized to 
have 95% of the PTV volume receive 95% of the prescription dose (47.5 Gy) therefore; nearly no 
difference was seen for D95% and V95%. BECT+VMAT has larger hotspots and therefor has higher Dmax, 
Dmin, and V107% as compared to the VMAT plans. Maximum and minimum dose was recorded from the 
TPS. In addition, among the VMAT techniques FFFVMAT6x has higher Dmax and V107%. The VMAT 
techniques had better conformity and homogeneity, essentially no difference among all three, than 
BECT+VMAT. All techniques were able to achieve greater than 99.5% tumor control probability.  
Table 3.2 Evaluation metrics for the PTV for patient CW4 










[%] CI DHI 
TCP 
[%] 
VMAT 49.9 54.3 24.2 47.6 95.3 0.02 0.72 0.12 99.60 
FFFVMAT6x 49.8 56.0 23.8 47.6 95.2 0.26 0.67 0.13 99.50 
FFFVMAT10x 49.8 54.4 24.5 47.6 95.2 0.02 0.68 0.13 99.60 
BECT+VMAT 50.9 59.4 35.9 47.4 94.8 4.56 0.55 0.17 99.80 
- - - - - FFFVMAT10x 
            VMAT 
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3.1.4 Lungs 
Table 3.3 overviews the evaluation metrics for the lungs for patient CW4. BECT+VMAT had the 
lowest mean dose of 7.5 Gy and FFFVMAT6x had the highest mean dose of 10.2 Gy. Both VMAT and 
FFFVMAT10x had comparable mean dose around 9.3 Gy. In addition, FFFVMAT10x showed the 
highest maximum dose of 52.2 Gy. Maximum dose was recorded from the TPS. BECT+VMAT had the 
lowest V5Gy and V10Gy as compared to the VMAT techniques whose values were all nearly the same. The 
plan acceptance criterion that the volume of lungs receiving at least 20 Gy be less than 20% was met by 
all the techniques with BECT+VMAT having the lowest. Consequently, BECT+VMAT had the lowest 
NTCP of 2.17% as compared to VMAT, FFFVMAT6x, and FFFVMAT10x who’s NTCP was 3.02%, 
3.68%, and 3.26%, respectively.  In addition, BECT+VMAT had the lowest SCCP of 13% as compared 
to the VMAT techniques, which were all above 15.73%. SCCP values shown were calculated using the 
linear dose-response model (see section 2.7.3). 
Table 3.3 Evaluation metrics for the lungs for patient CW4 













VMAT 9.2 47.4 50.6 29.5 14.1 3.02 15.73 
FFFVMAT6x 10.2 52.2 51.6 28.0 16.8 3.68 17.40 
FFFVMAT10x 9.5 51.0 46.8 29.7 15.8 3.26 16.35 
BECT+VMAT 7.5 49.3 33.5 20.5 11.8 2.17 13.00 
 
3.1.5 Heart 
Table 3.4 summarizes the evaluation metrics for the heart for patient CW4. BECT+VMAT 
showed the largest improvement in the mean dose with a reduction of nearly 3 Gy. The VMAT 
techniques had comparable mean heart dose of approximately 9.5 Gy and BECT+VMAT had a mean 
heart dose of 6.7 Gy. The maximum dose was comparable for all techniques with FFFVMAT6x 
exhibiting the highest. Maximum dose was recorded from the TPS. V5Gy and V10Gy was comparable for all 
VMAT techniques and significantly lower for BECT+VMAT. All techniques met the acceptance criteria 
that the volume of heart receiving at least 22.5 Gy be less than 20% with BECT+VMAT being the lowest 
at 1.5%. V30Gy, associated with cardiac mortality, was 0.0% for BECT+VMAT, 1.8% for VMAT, and 
even higher for both FFFVMAT techniques. Whole Heart NTCP was lowest for BECT/IXMT followed 
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by VMAT, FFFVMAT10x, and FFFVMAT6x with values of 0.03%, 0.31%, 0.50%, and 0.61%, 
respectively. Myocardium NTCP followed the same trend with the lowest being BECT/ IXMT followed 
by VMAT, FFFVMAT10x, and FFFVMAT6x with values of 0.07%, 0.57%, 0.87%, and 1.11%, 
respectively.  
Table 3.4 Evaluation metrics for the heart for patient CW4 















VMAT 9.2 38.4 59.8 29.4 9.2 1.8 0.31 0.57 
FFFVMAT6x 9.7 45.2 65.6 27.7 11.3 4.5 0.61 1.11 
FFFVMAT10x 9.5 41.4 59.4 31.0 11.2 3.4 0.50 0.87 
BECT+VMAT 6.7 34.5 48.4 16.5 1.5 0.0 0.03 0.07 
 
3.1.6 Contralateral Breast 
Table 3.5 summarizes the evaluation metrics for the contralateral breast for patient CW4. The 
mean dose for the right breast was reduced by over 2 Gy using BECT+VMAT as compared to VMAT. 
There was less of a difference with FFFVMAT10x with only a 1 Gy reduction in dose. Both VMAT and 
FFFVMAT6x had very similar mean dose to the contralateral breast. In contrast, the maximum dose was 
exhibited by the BECT+VMAT plan, which is nearly twice as high as any of the VMAT techniques. 
Maximum dose was recorded from the TPS. The volume of the contralateral breast receiving at least 5 Gy 
was significantly reduced by BECT+VMAT over any VMAT technique. SCCP was lowest for 
BECT/IXMT followed by FFFVMAT10x, FFFVMAT6x, and VMAT with values of 1.87%, 2.41%, 
3.10%, and 3.24%, respectively. SCCP values shown were calculated using the linear dose-response 
model (see section 2.7.3). 
Table 3.5 Evaluation metrics for the contralateral breast for patient CW4 







VMAT 4.2 19.7 19.4 3.24 
FFFVMAT6x 4.0 18.4 19.1 3.10 
FFFVMAT10x 3.1 15.7 17.0 2.41 





Table 3.6 summarizes the evaluation metrics for the skin for patient CW4. The mean dose for all 
techniques was comparable and very close to the prescription dose (50 Gy). In addition, the minimum 
dose for all techniques was similar. The maximum dose was highest for BECT+VMAT with a value of 
58.1 Gy. Among the VMAT techniques the highest dose was seen with FFFVMAT6x followed by 
VMAT and FFFVMAT10x with values of 56.0 Gy, 54.6 Gy, and 53.4 Gy, respectively. All techniques 
for this plan had TV-V110% less than 5.13% so the patient does not show an increased risk of moist 
desquamation. 
Table 3.6 Evaluation metrics for the skin (5 mm shell) for patient CW4 








VMAT 49.8 54.6 35.3 0.00 
FFFVMAT6x 49.5 56.0 36.4 0.12 
FFFVMAT10x 49.2 53.4 38.6 0.00 
BECT+VMAT 50.5 58.1 36.6 0.50 
 
3.2 Overview of Results for the Sample of Patients 
The following sections give an overview of the results for the entire sample of patients for this 
study. The data will be discussed in terms of mean values for each metric along with any statistical 
significance. For all ten patients, VMAT and FFFVMAT (6x and 10x) plans were produced. Only nine of 
the patients were used for BECT+VMAT. The tenth patient was not used for BECT+VMAT because the 
PTV extended all the way to the rib-lung. Due to an uneven number of patients for each technique, 
statistical analysis was determined using a mixed model approach with a significance level of p = 0.05 
(Guo et al., 2015). Statistical comparison was conducted as VMAT vs. FFFVMAT6x, VMAT vs. 
FFFVMAT10x, and VMAT vs. BECT+VMAT.  
3.2.1 PTV 
Tables 3.7 - 3.10 list the dosimetric and radiobiological metrics used to evaluate the PTV for 
VMAT, FFFVMAT6x, FFFVMAT10x, and BECT+VMAT treatment plans. The maximum dose for all 
VMAT plans was comparable with no statistical significance (p > 0.05). Due to the hotspots in the 
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BECT+VMAT, the maximum dose to the PTV was significantly higher (p < 0.001) than VMAT.  The 
minimum dose for all VMAT plans was comparable with no statistical significance (p > 0.05). The 
overall PTV dose was higher for BECT+VMAT plans so the minimum dose was statistically significantly 
higher (p = 0.015) than VMAT plans. All plans were normalized to have 95% of the PTV volume receive 
95% of the prescription dose (47.5 Gy) therefore; no statistically significant difference was expected or 
seen for 𝐷95% and 𝑉95% between all techniques. No significant difference was shown for 𝑉107% for any 
VMAT technique. However, BECT+VMAT had 13.7% of the PTV volume receive over 107% of the 
prescription dose (p < 0.001). The VMAT techniques showed good conformity of the dose to the PTV 
with no significant difference seen between them (p > 0.05). BECT+VMAT was less conformal than 
VMAT (p = 0.001). Dose homogeneity was similar for all VMAT techniques with no statistically 
significant difference (p > 0.05). Again, BECT+VMAT exhibited less dose homogeneity than VMAT (p 
< 0.001). Mean tumor control probability was 98.6±1.6% for VMAT, 98.7±1.4% for FFFVMAT6x, 
99.5±0.7% for FFFVMAT10x, and 99.7±0.1% for BECT+VMAT with no statistical difference between 
each technique and VMAT (p > 0.05). 
3.2.2 Lungs 
Tables 3.11 – 3.14 list the dosimetric and radiobiological metrics used to evaluate the lungs for 
VMAT, FFFVMAT6x, FFFVMAT10x, and BECT+VMAT treatment plans. No difference is seen for the 
mean dose for each technique compared to VMAT. All techniques had statistically significant higher 
maximum lung dose as compared to VMAT (p < 0.05). The volume of lungs receiving at least 5 Gy was 
significantly higher for both FFFVMAT (6x and 10x) techniques compared to VMAT. However, 
BECT+VMAT showed nearly 10% reduction in volume of lungs receiving at least 5 Gy (p = 0.001). The 
volume of lungs receiving at least 10 Gy was statistically insignificant for any technique over VMAT. 
The high dose region of lungs, volume of lungs receiving at least 20 Gy, was significantly higher for all 
techniques compared to VMAT (p < 0.05) but still under the 20% requirement of the plan acceptance 
criteria. No statistically significant difference was seen for any technique over VMAT for 𝑁𝑇𝐶𝑃 and 
𝑆𝐶𝐶𝑃 for the lungs. 
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3.2.3 Heart 
Tables 3.15 – 3.18 list the dosimetric and radiobiological metrics used to evaluate the heart for 
VMAT, FFFVMAT6x, FFFVMAT10x, and BECT+VMAT treatment plans. BECT+VMAT showed a 1.3 
Gy reduction in mean dose to the heart compared to VMAT with values of 7.7±1.4 Gy and 9.0±1.5 Gy, 
respectively. However, no statistically significant difference was determined between the two (p = 0.063). 
In addition, FFFVMAT6x had a significantly higher mean lung dose over VMAT (p = 0.017) while no 
significant difference was seen between FFFVMAT10x and VMAT (p = 0.062). There was no 
statistically significant difference between any technique and VMAT for the maximum heart dose. The 
volume of heart receiving at least 5 Gy was significantly lower, over 10%, for BECT+VMAT over 
VMAT (p = 0.032). There was no significant difference between any FFFVMAT technique compared to 
VMAT for the volume of heart receiving at least 5 Gy (p > 0.05). Furthermore, no statistically significant 
difference was seen between any technique and VMAT for the volume of heart receiving at least 10 Gy. It 
was shown that both FFFVMAT6x and FFFVMAT10x had increased volume of heart receiving at least 
22.5 Gy over VMAT. The volume of heart receiving at least 22.5 Gy was decreased for BECT+VMAT. It 
was also shown that both FFFVMAT6x and FFFVMAT10x had increased volume of heart receiving at 
least 30 Gy over VMAT and the volume of heart receiving at least 30 Gy was decreased for 
BECT+VMAT. The patient averaged predicted risk of cardiac mortality (𝑁𝑇𝐶𝑃) for the whole heart was 
statistically significantly higher for FFFVMAT6x (p = 0.013) and was statistically significantly lower for 
BECT+VMAT (p = 0.047). The whole heart 𝑁𝑇𝐶𝑃 was determined to be 0.72±0.56% for VMAT, 
0.94±0.58% for FFFVMAT6x (p = 0.013), 0.92±0.55% for FFFVMAT10x (p = 0.114), and 0.28±0.28% 
for BECT+VMAT (p = 0.047).  Furthermore, the patient averaged predicted risk of cardiac mortality 
(𝑁𝑇𝐶𝑃) for the myocardium was statistically significantly higher for FFFVMAT6x (p = 0.011) and no 
statistically significant difference was determined for either FFFVMAT10x (p = 0.099) or BECT+VMAT 
(p = 0.054) over VMAT. The myocardium 𝑁𝑇𝐶𝑃  was determined to be 1.14±0.91% for VMAT, 
1.49±1.00% for FFFVMAT6x (p = 0.011), 1.45±0.96% for FFFVMAT10x (p = 0.099), and 0.43±0.42% 
for BECT+VMAT (p = 0.054). 
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3.2.4 Contralateral Breast 
Tables 3.19 and 3.20 list the dosimetric and radiobiological metrics used to evaluate the 
contralateral breast for VMAT, FFFVMAT6x, FFFVMAT10x, and BECT+VMAT treatment plans. No 
statistically significance was seen between FFFVMAT10x and VMAT for the mean dose to the 
contralateral breast (p = 0.781). There was a statistically significant decrease in mean dose to the 
contralateral breast between FFFVMAT6x and VMAT (p = 0.025) as well as with BECT+VMAT and 
VMAT (p < 0.001). The mean dose was reduced by 1.8 Gy for BECT+VMAT over VMAT. There was no 
statistically significant difference seen for the maximum dose to the contralateral breast between any 
technique and VMAT. In addition, the volume of contralateral breast receiving at least 5 Gy was 
statistically significantly reduced for FFFVMAT6x and VMAT (p = 0.032) as well as with 
BECT+VMAT and VMAT (p = 0.001) with values of 22.6±12.4% for VMAT, 15.4±8.5% for 
FFFVMAT6x, and 4.3±2.7% for BECT+VMAT. No significant difference was seen between VMAT and 
FFFVMAT10x (p = 0.925). The same trend was observed for the patient averaged SCCP for the 
contralateral breast with statistically significant reduction for FFFVMAT6x and VMAT (p = 0.026) as 
well as with BECT+VMAT and VMAT (p < 0.001) with values of 3.03±0.88% for VMAT, 2.55±0.63% 
for FFFVMAT6x, and 1.50±0.50% for BECT+VMAT. No significant difference was seen between 
VMAT and FFFVMAT10x (p = 0.737). 
3.2.5 Skin 
Tables 3.21 and 3.22 list the dose volume metrics used to evaluate the skin (5 mm shell) for each 
patient. No statistically significant difference for the mean skin dose was seen between any FFFVMAT 
plans compared to VMAT (p > 0.05). The hotspots seen in the BECT+VMAT plans show a statistically 
significant increase in mean skin dose over VMAT (p < 0.001). There was no statistically significant 
difference in the maximum skin dose between FFFVMAT6x and VMAT (p = 0.724). However, a 
statistically significant reduction in the maximum skin dose was seen with FFFVMAT10x (p = 0.039). A 
statistically significant increase in maximum skin dose with BECT+VMAT as compared to VMAT (p < 
0.001) was seen with values of 53.3±0.7 Gy for VMAT and 59.3±2.1 Gy for BECT+VMAT. There was 
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no statistically significant difference in minimum skin dose for any technique compared to VMAT. No 
statistically significant difference was shown for 𝑇𝑉 − 𝑉110% between the VMAT techniques. Again, 
BECT+VMAT had higher 𝑇𝑉 − 𝑉110% than VMAT (p < 0.001). Fortunately, All techniques for this 
patient had 𝑇𝑉 − 𝑉 110% less than 5.13% so the patient does not show an increased risk of moist 
desquamation of the skin. 
3.2.6 Treatment Time and Total Number of Monitor Units 
 Table 3.23 lists the treatment times for VMAT, FFFVMAT6x, and FFFVMAT10x treatment 
plans. No statistical significance was observed between FFFVMAT6x and VMAT or between 
FFFVMAT10x and VMAT for deliveries of Arc 1. FFFVMAT6x (p < 0.001) and FFFVMAT10x (p < 
0.001) showed a statistically significant reduction in delivery time of Arc 2 over VMAT with mean times 
of 49±1 seconds for FFFVMAT6x, 47±1 seconds for FFFVMAT10x, and 61±1 seconds for VMAT.  In 
addition, FFFVMAT6x (p = 0.001) and FFFVMAT10x (p = 0.004) showed a statistically significant 
reduction in mean delivery of total treatment time over VMAT with times of 2 min 20 seconds ±1 
seconds for FFFVMAT6x, 2 min 18 seconds ±7 seconds for FFFVMAT10x, and 2 min 36 seconds ±5 
seconds for VMAT.   
 Table 3.24 lists the total number of monitor units (MU) reported by the TPS for VMAT, 
FFFVMAT6x, and FFFVMAT10x treatment plans. The monitor units were recorded for Arc 1, Arc 2, and 
total number of monitor units. Total number of monitor units is the sum of both arcs. Increased monitor 
units represent a more modulated beam delivery and results in a more complex treatment plan. Both 
FFFVMAT6x (p < 0.001) and FFFVMAT10x (p < 0.001) had a statistically significant increase in mean 
monitor units for Arc 1 and Arc 2 compared to VMAT. In addition, Both FFFVMAT6x (p < 0.001) and 
FFFVMAT10x (p < 0.001) had a statistically significant increase in mean total MU compared to VMAT 






Table 3.7 Selected PTV evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: Dmax = maximum dose; Dmin = minimum dose; FFFVMAT6x p-value = 
VMAT vs. FFFVMAT6x; FFFVMAT10x p-value = VMAT vs. FFFVMAT10x; BECT+VMAT p-value = 
VMAT vs. BECT+VMAT. 
Patient 












1 54.3 53.0 52.7 65.0 11.7 12.0 11.7 15.6 
2 53.2 52.7 52.9 59.0 18.5 20.7 22.8 29.7 
3 53.3 52.9 53.1 60.2 22.8 26.4 26.3 31.5 
4 54.3 56.0 54.4 59.4 24.2 23.8 24.5 35.9 
5 54.3 53.2 53.5 62.8 16.7 22.6 23.2 21.9 
6 53.1 54.2 52.7 62.7 29.7 28.5 30.3 29.2 
7 53.0 52.4 53.6 60.3 28.1 29.2 28.8 23.4 
8 52.7 52.9 52.8 60.6 22.1 22.0 21.8 25.0 
9 52.9 52.6 53.6 60.2 13.9 11.3 13.8 25.8 
10 52.8 53.2 52.9 - 18.6 16.7 16.5 - 
Mean 53.4 53.3 53.2 61.1 20.6 21.3 22.0 26.4 
σ 0.7 1.1 0.5 1.9 5.8 6.3 6.2 6.0 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.787 0.433 <0.001 0.418 0.134 0.015 
 
Table 3.8 Selected PTV evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: D95% = dose that 95% of the volume receives; V95% = volume that receives 
95% of the prescription dose; NS = no statistical significance. 
Patient 












1 47.4 47.4 47.5 47.4 94.9 94.8 95.1 94.8 
2 47.6 47.5 47.4 47.4 95.3 95.0 94.4 94.7 
3 47.4 47.6 47.5 47.6 94.7 95.3 95.1 95.2 
4 47.6 47.6 47.6 47.4 95.3 95.2 95.2 94.8 
5 47.4 47.6 47.6 47.4 94.6 95.2 95.3 94.9 
6 47.5 47.4 47.5 47.5 94.8 94.8 95.0 95.0 
7 47.6 47.6 47.4 47.4 95.2 95.2 94.5 94.8 
8 47.5 47.4 47.5 47.5 95.1 94.8 94.8 94.9 
9 47.5 47.5 47.6 47.5 95.0 95.0 95.3 95.0 
10 47.6 47.6 47.4 - 95.2 95.2 94.8 - 
Mean 47.5 47.5 47.5 47.5 95.0 95.1 94.9 94.9 
σ 0.1 0.1 0.1 0.1 0.2 0.2 0.3 0.1 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
NS NS NS NS NS NS 
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Table 3.9 Selected PTV evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: V107% = volume that receives 107% of the prescription dose; CI = 
conformity index. 
Patient 












1 0.16 0.00 0.00 11.10 0.68 0.71 0.71 0.65 
2 0.00 0.00 0.00 30.45 0.73 0.71 0.76 0.51 
3 0.00 0.00 0.00 12.74 0.65 0.64 0.66 0.57 
4 0.02 0.26 0.02 4.56 0.72 0.67 0.68 0.55 
5 0.05 0.00 0.00 13.20 0.67 0.68 0.73 0.73 
6 0.00 0.01 0.00 18.00 0.67 0.68 0.70 0.55 
7 0.00 0.00 0.00 11.68 0.77 0.73 0.75 0.63 
8 0.00 0.00 0.00 7.09 0.68 0.63 0.65 0.53 
9 0.00 0.00 0.00 14.54 0.69 0.67 0.67 0.62 
10 0.00 0.00 0.00 - 0.82 0.78 0.81 - 
Mean 0.02 0.03 0.00 13.71 0.71 0.69 0.71 0.59 
σ 0.1 0.1 0.0 7.4 0.05 0.04 0.05 0.07 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
1.000 0.193 <0.001 0.071 0.708 0.001 
 
Table 3.10 Selected PTV evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: DHI = dose homogeneity index; TCP = tumor control probability. 
Patient 












1 0.16 0.13 0.14 0.23 97.6 97.6 99.7 99.6 
2 0.13 0.13 0.10 0.21 97.5 97.5 99.8 99.8 
3 0.13 0.13 0.12 0.24 99.8 99.8 99.8 99.9 
4 0.12 0.13 0.13 0.17 99.6 99.5 99.6 99.8 
5 0.15 0.12 0.12 0.22 94.8 99.6 99.7 99.5 
6 0.13 0.13 0.12 0.23 99.7 99.8 99.8 99.6 
7 0.10 0.11 0.12 0.20 99.7 99.7 99.7 99.8 
8 0.12 0.13 0.11 0.20 99.8 99.8 99.8 99.9 
9 0.10 0.12 0.12 0.22 99.4 98.2 99.3 99.7 
10 0.13 0.16 0.15 - 98.3 95.6 97.7 - 
Mean 0.12 0.13 0.12 0.21 98.6 98.7 99.5 99.7 
σ 0.02 0.01 0.02 0.02 1.6 1.4 0.7 0.1 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 




Table 3.11 Selected lung evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: Dmean = mean dose; Dmax = maximum dose; NS = no statistical 
significance; FFFVMAT6x p-value = VMAT vs. FFFVMAT6x; FFFVMAT10x p-value = VMAT vs. 
FFFVMAT10x; BECT+VMAT p-value = VMAT vs. BECT+VMAT. 
Patient 












1 8.7 9.0 9.3 8.3 49.9 52.5 49.5 51.2 
2 8.5 9.0 8.8 6.6 48.5 50.5 49.0 50.5 
3 8.8 10.2 10.3 8.6 51.2 50.7 52.2 52.6 
4 9.2 10.2 9.5 7.5 47.4 52.2 51.0 49.3 
5 8.4 9.6 9.2 8.3 49.6 52.6 51.7 53.6 
6 9.9 10.8 10.5 9.3 51.2 52.6 51.3 54.7 
7 8.6 9.0 9.1 9.5 47.0 47.8 49.5 54.3 
8 8.0 8.3 8.7 9.4 50.0 51.3 50.4 53.2 
9 8.0 8.2 8.5 8.6 46.3 49.9 49.7 51.2 
10 8.9 9.0 9.9 - 51.0 52.0 51.5 - 
Mean 8.7 9.3 9.4 8.5 49.2 51.2 50.6 52.3 
σ 0.6 0.9 0.7 0.9 1.8 1.5 1.1 1.8 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
NS NS NS 0.003 0.014 0.001 
 
Table 3.12 Selected lung evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: V5Gy = volume that receives at least 5 Gy; V10Gy = volume that receives at 
least 10 Gy; NS = no statistical significance. 
Patient 












1 41.4 48.1 45.1 32.4 23.5 23.2 23.8 23.3 
2 41.3 42.2 43.9 30.4 22.7 23.1 22.9 19.4 
3 41.7 51.7 57.3 38.3 22.9 27.8 26.6 23.3 
4 50.6 51.6 46.8 33.5 29.5 28.0 29.7 20.5 
5 41.3 42.1 43.3 36.5 22.7 25.8 24.8 22.5 
6 54.7 58.5 59.9 34.9 26.7 32.0 29.9 23.2 
7 47.7 51.9 55.1 38.2 25.3 27.1 27.3 25.1 
8 39.1 42.6 41.6 32.2 22.1 22.5 23.1 26.3 
9 37.4 34.9 38.7 31.3 23.4 23.5 23.5 23.1 
10 39.9 39.1 45.2 - 25.7 24.7 28.1 - 
Mean 43.5 46.3 47.7 34.2 24.5 25.8 26.0 22.9 
σ 5.6 7.2 7.2 2.9 2.3 3.0 2.7 2.1 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.042 0.027 0.001 NS NS NS 
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Table 3.13 Selected lung evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: V20Gy = volume that receives at least 20 Gy; NTCP = normal tissue 
complication probability; NS = no statistical significance. 
Patient 












1 13.4 12.6 13.6 15.6 2.73 2.87 3.03 2.58 
2 13.5 14.0 13.6 11.6 2.66 2.94 2.79 1.80 
3 13.1 15.1 15.1 15.0 2.81 3.65 3.70 2.71 
4 14.1 16.8 15.8 11.8 3.02 3.68 3.26 2.17 
5 13.3 15.0 14.7 14.8 2.59 3.32 3.10 2.56 
6 14.3 15.0 14.7 16.7 3.43 4.10 3.87 3.15 
7 11.0 11.5 11.6 17.2 2.65 2.87 2.95 3.28 
8 12.4 12.6 14.2 19.7 2.38 2.52 2.75 3.20 
9 12.1 13.0 13.0 17.0 2.38 2.51 2.63 2.80 
10 15.0 15.5 16.2 - 2.91 2.98 3.47 - 
Mean 13.2 14.1 14.3 15.5 2.76 3.14 3.16 2.69 
σ 1.2 1.6 1.4 2.6 0.3 0.5 0.4 0.5 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.020 0.001 0.023 NS NS NS 
 
Table 3.14 Selected lung evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 









1 14.92 15.29 15.74 14.39 
2 14.65 15.47 15.03 11.51 
3 15.11 17.35 17.45 14.80 
4 15.73 17.40 16.35 13.00 
5 14.43 16.50 15.93 14.31 
6 16.81 18.37 17.85 16.03 
7 14.64 15.31 15.55 16.39 
8 13.75 14.19 14.93 16.16 
9 13.74 14.16 14.55 15.05 
10 15.39 15.57 16.89 - 
Mean 14.92 15.96 16.03 14.63 
σ 0.9 1.4 1.1 1.6 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
NS NS NS 
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Table 3.15 Selected heart evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: Dmean = mean dose; Dmax = maximum dose; NS = no statistical 
significance; FFFVMAT6x p-value = VMAT vs. FFFVMAT6x; FFFVMAT10x p-value = VMAT vs. 
FFFVMAT10x; BECT+VMAT p-value = VMAT vs. BECT+VMAT. 
Patient 












1 9.0 10.5 10.6 8.1 43.0 45.0 44.3 39.5 
2 10.2 11.2 10.8 6.2 41.3 44.6 45.2 36.9 
3 7.0 9.4 9.6 7.9 40.2 43.4 43.9 40.5 
4 9.2 9.7 9.5 6.7 38.4 45.2 41.4 34.5 
5 10.0 12.0 11.8 6.6 47.5 48.6 48.0 36.9 
6 10.9 12.6 10.5 10.1 49.1 49.8 45.8 44.3 
7 9.4 9.6 9.0 9.6 43.6 43.0 45.3 46.9 
8 9.3 9.3 10.0 6.7 43.4 44.7 45.8 43.9 
9 9.2 9.3 9.2 6.9 39.0 43.2 44.7 40.3 
10 5.8 5.3 5.7 - 31.7 38.3 39.3 - 
Mean 9.0 9.9 9.7 7.7 41.7 44.6 44.4 40.4 
σ 1.5 2.0 1.6 1.4 4.9 3.2 2.4 4.0 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.017 0.062 0.063 NS NS NS 
 
Table 3.16 Selected heart evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: V5Gy = volume that receives at least 5 Gy; V10Gy = volume that receives at 
least 10 Gy; NS = no statistical significance. 
Patient 












1 56.4 72.5 72.1 50.1 25.8 31.3 30.5 27.0 
2 82.8 86.0 79.6 40.2 25.1 28.2 29.8 16.0 
3 43.3 69.6 69.9 54.3 15.6 23.9 30.2 26.1 
4 59.8 65.6 59.4 48.4 29.4 27.7 31.0 16.5 
5 64.9 79.4 75.6 49.9 24.9 33.6 35.2 17.3 
6 85.2 93.4 80.8 69.8 29.2 45.7 30.7 32.0 
7 68.6 65.2 63.5 68.2 26.7 29.0 24.5 27.7 
8 67.6 65.7 69.9 41.1 26.6 26.8 27.1 19.5 
9 73.3 64.0 60.1 45.0 24.1 22.5 23.2 17.7 
10 51.1 42.3 44.8 - 10.7 7.7 10.9 - 
Mean 65.3 70.4 67.6 51.9 23.8 27.6 27.3 22.2 
σ 13.2 14.0 10.9 10.7 6.0 9.5 6.7 6.0 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.197 0.564 0.032 NS NS NS 
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Table 3.17 Selected heart evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: V22.5Gy = volume that receives at least 22.5 Gy; V30Gy = volume that 
receives at least 30 Gy. 
Patient 












1 9.7 11.9 12.7 6.4 5.1 6.6 7.8 0.9 
2 11.0 12.8 12.5 3.5 7.2 8.1 7.4 0.5 
3 5.5 10.0 8.7 5.9 1.9 5.5 3.4 1.4 
4 9.2 11.3 11.2 1.5 1.8 4.5 3.4 0.0 
5 12.2 14.6 14.1 3.3 9.1 10.9 10.5 0.2 
6 11.5 12.1 10.7 10.8 7.8 7.3 6.2 4.4 
7 8.7 10.1 9.0 10.3 3.8 4.3 4.0 5.1 
8 10.1 9.8 11.6 4.8 4.6 5.4 6.6 1.6 
9 9.9 11.0 11.4 3.1 3.8 5.7 6.8 0.6 
10 0.2 0.8 1.0 - 0.0 0.2 0.2 - 
Mean 8.8 10.4 10.3 5.5 4.5 5.9 5.6 1.6 
σ 3.5 3.7 3.6 3.2 2.9 2.8 2.9 1.8 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.003 0.003 0.050 0.007 0.031 0.032 
 
Table 3.18 Selected heart evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: NTCP = normal tissue complication probability. 
Patient 












1 0.65 1.02 1.30 0.19 1.04 1.61 2.03 0.32 
2 1.00 1.23 1.11 0.10 1.49 1.84 1.66 0.15 
3 0.26 0.75 0.50 0.23 0.36 1.08 0.72 0.33 
4 0.31 0.61 0.50 0.03 0.57 1.11 0.87 0.07 
5 1.69 2.20 2.05 0.08 2.97 3.84 3.62 0.16 
6 1.60 1.40 0.98 0.67 2.37 2.10 1.47 1.04 
7 0.54 0.58 0.59 0.83 0.80 0.88 0.86 1.23 
8 0.64 0.78 1.01 0.24 1.01 1.21 1.60 0.37 
9 0.48 0.77 1.08 0.11 0.75 1.19 1.65 0.17 
10 0.01 0.03 0.04 - 0.01 0.03 0.04 - 
Mean 0.72 0.94 0.92 0.28 1.14 1.49 1.45 0.43 
σ 0.56 0.58 0.55 0.28 0.91 1.00 0.96 0.42 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 




Table 3.19 Selected contralateral breast evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, 
and BECT+VMAT. Abbreviations: Dmean = mean dose; Dmax = maximum dose; NS = no statistical 
significance; FFFVMAT6x p-value = VMAT vs. FFFVMAT6x; FFFVMAT10x p-value = VMAT vs. 
FFFVMAT10x; BECT+VMAT p-value = VMAT vs. BECT+VMAT. 
Patient 












1 3.8 3.5 3.8 1.5 18.7 22.7 23.8 18.4 
2 2.7 2.5 3.8 1.1 24.4 19.6 26.5 26.3 
3 5.8 4.1 4.5 1.9 32.2 26.7 29.0 34.0 
4 4.2 4.0 3.1 2.1 19.7 18.4 15.7 30.1 
5 2.4 1.8 2.5 1.2 21.5 22.5 20.6 21.7 
6 4.7 3.8 5.5 2.3 41.4 39.9 41.6 44.2 
7 3.1 3.5 4.4 1.4 21.6 20.1 24.1 26.7 
8 4.0 3.8 2.9 1.0 25.7 27.1 23.1 20.6 
9 4.9 2.8 3.4 2.5 38.9 31.7 34.7 43.4 
10 2.6 2.3 3.4 - 16.5 13.4 16.6 - 
Mean 3.8 3.2 3.7 1.7 26.1 24.2 25.6 29.5 
σ 1.1 0.8 0.9 0.6 8.6 7.5 7.9 9.4 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.025 0.781 <0.001 NS NS NS 
 
Table 3.20 Selected contralateral breast evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, 
and BECT+VMAT. Abbreviations: V5Gy = volume that receives at least 5 Gy; SCCP = second cancer 
complication probability. 
Patient 












1 22.6 19.3 23.4 3.2 2.99 2.73 2.96 1.27 
2 9.3 6.8 21.1 2.3 2.13 1.96 3.00 1.05 
3 45.1 26.3 32.5 4.4 4.57 3.25 3.55 1.63 
4 19.4 19.1 17.0 7.5 3.24 3.10 2.41 1.87 
5 11.2 3.7 6.8 1.2 1.92 1.47 1.93 1.09 
6 24.8 21.8 46.8 7.2 3.74 3.10 4.33 2.12 
7 17.3 18.0 27.3 3.3 2.47 2.71 3.43 1.32 
8 27.8 24.0 12.0 1.3 3.22 3.05 2.32 0.88 
9 40.3 12.5 23.2 8.2 3.92 2.34 2.76 2.28 
10 8.5 2.4 12.3 - 2.06 1.79 2.66 - 
Mean 22.6 15.4 22.2 4.3 3.03 2.55 2.94 1.50 
σ 12.4 8.5 11.6 2.7 0.88 0.63 0.69 0.50 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.032 0.925 0.001 0.026 0.737 <0.001 
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Table 3.21 Selected skin (5mm shell) evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: Dmean = mean dose; Dmax = maximum dose; FFFVMAT6x p-value = 
VMAT vs. FFFVMAT6x; FFFVMAT10x p-value = VMAT vs. FFFVMAT10x; BECT+VMAT p-value = 
VMAT vs. BECT+VMAT. 
Patient 












1 49.2 48.9 48.7 49.7 54.2 52.7 52.7 63.4 
2 48.8 48.6 48.0 50.6 53.2 52.5 52.3 58.0 
3 49.0 49.0 48.9 50.3 52.9 52.9 52.5 57.1 
4 49.8 49.5 49.2 50.5 54.6 56.0 53.4 58.1 
5 49.9 49.6 49.2 50.3 53.5 52.9 53.4 60.3 
6 49.3 49.6 49.2 51.0 53.1 54.2 52.7 59.9 
7 49.2 49.3 49.1 50.6 52.9 52.3 52.8 60.3 
8 49.3 49.8 49.4 50.7 52.6 52.8 52.4 56.5 
9 49.2 49.1 49.4 50.4 52.9 52.3 53.3 60.2 
10 49.3 49.4 49.6 - 52.8 53.2 52.6 - 
Mean 49.3 49.3 49.1 50.5 53.3 53.2 52.8 59.3 
σ 0.3 0.4 0.5 0.4 0.7 1.1 0.4 2.1 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
0.838 0.100 <0.001 0.724 0.039 <0.001 
 
Table 3.22 Selected skin (5mm shell) evaluation metrics for VMAT, FFFVMAT6x, FFFVMAT10x, and 
BECT+VMAT. Abbreviations: Dmin = minimum dose; TV-V110% = percent volume receiving 110% of the 
prescription dose within treated volume; NS = no statistical significance. 
Patient 












1 3.8 3.9 3.7 0.0 0.00 0.00 0.00 4.01 
2 0.3 4.3 4.6 0.0 0.00 0.00 0.00 5.89 
3 19.2 18.8 18.3 11.4 0.00 0.00 0.00 1.57 
4 35.3 36.4 38.6 36.6 0.00 0.12 0.00 0.50 
5 35.4 33.8 31.4 19.6 0.00 0.00 0.00 5.20 
6 35.4 35.8 29.4 7.5 0.00 0.00 0.00 4.26 
7 32.0 34.2 31.9 23.4 0.00 0.00 0.00 4.20 
8 22.1 22.0 21.8 25.0 0.00 0.00 0.00 2.63 
9 13.9 14.1 13.8 28.1 0.00 0.00 0.00 4.46 
10 28.7 30.0 29.4 - 0.00 0.00 0.00 - 
Mean 22.6 23.3 22.3 16.8 0.00 0.01 0.00 3.64 
σ 13.1 12.7 12.0 12.8 0.0 0.0 0.0 1.7 
p-value FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT FFFVMAT6x FFFVMAT10x 
BECT+ 
VMAT 
NS NS NS 0.343 NA* <0.001 
* both groups  contain only 0's, therefore variance cannot be calculated 
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Table 3.23 Treatment time for VMAT, FFFVMAT6x, and FFFVMAT10x. Abbreviations: FFFVMAT6x 
p-value = VMAT vs. FFFVMAT6x; FFFVMAT10x p-value = VMAT vs. FFFVMAT10x; NS = no 
statistical significance. 
fx 






















1 0:57 0:55 0:51 1:01 0:50 0:47 2:43 2:20 2:12 
2 0:56 0:54 0:49 1:00 0:48 0:47 2:35 2:18 2:13 
3 0:56 0:53 0:57 1:01 0:50 0:48 2:34 2:21 2:24 
4 0:56 0:54 0:57 1:01 0:49 0:47 2:33 2:21 2:24 
Mean 0:56 0:54 0:54 1:01 0:49 0:47 2:36 2:20 2:18 














NS NS <0.001 <0.001 0.001 0.004 
 
Table 3.24 Total number of monitor units for VMAT, FFFVMAT6x, and FFFVMAT10x. Abbreviations: 
FFFVMAT6x p-value = VMAT vs. FFFVMAT6x; FFFVMAT10x p-value = VMAT vs. FFFVMAT10x. 
Patient 






















1 240 371 484 231 355 259 471 726 743 
2 243 404 473 198 295 326 441 699 799 
3 324 404 399 178 266 307 502 670 706 
4 198 328 438 275 316 367 473 644 805 
5 195 231 397 229 366 352 424 597 749 
6 282 355 336 246 339 399 528 694 735 
7 262 381 390 229 265 367 491 646 757 
8 210 394 370 267 301 299 477 695 669 
9 199 276 276 254 297 428 453 573 704 
10 235 302 307 189 239 303 424 541 610 
Mean 238.8 344.6 387 229.6 303.9 340.7 468.4 648.5 727.7 


















Chapter 4 Discussion 
This study compared four advanced radiotherapy techniques for treating post-mastectomy breast 
cancer patients. VMAT, FFFVMAT6x, FFFVMAT10x, and BECT+VMAT plans were created 
retrospectively for ten left-sided post-mastectomy patients. The major goal of this study was to determine 
if BECT+VMAT and FFFVMAT (6x and 10x) can maintain equal or better dose coverage of the PTV 
than VMAT while reducing doses to OARs. In addition, it was important to predict the SCCP and NTCP 
associated with each technique and determine if any statistically significant difference can be ascertained 
between the techniques as compared to VMAT. The hypothesis of this study was that for a selected group 
of post-mastectomy breast cancer patients, BECT+VMAT and FFFVMAT (6x and 10x) could maintain 
equal or better dose coverage than VMAT while statistically significantly lowering (p < 0.05) predicted 
risks of side effects to the lungs, heart, and contralateral breast. The results of this study support that 
BECT+VMAT and FFFVMAT6x and FFFVMAT10x treatment plans can maintain equal or better dose 
coverage than VMAT even though BECT+VMAT treatment plans consistently contained hot spots. 
However, both FFFVMAT (6x and 10x) plans showed little improvement in reducing predicted risk of 
side effects with the exception of FFFVMAT6x reducing the SCCP of the contralateral breast over 
VMAT. Both FFFVMAT6x and FFFVMAT10x were able to significantly reduce the total treatment time 
over VMAT. BECT+VMAT was able to reduce the risk of side effects with statistical significance for the 
whole heart and contralateral breast compared to VMAT. 
The key results for the specific aims of this work are presented in sections 4.1 and 4.2. The 
implications and significance of the results, strengths and limitations of this work, and possible future 
work will be discussed in sections 4.3 - 4.5. 
4.1 Outcomes of Specific Aim One 
Specific aim one compared treatment plans and predicted risks of side effects between 
BECT+VMAT and VMAT plans. This was achieved by creating comprehensive dose reconstructions, 
calculating tumor control probability, determine normal tissue complication probability for the whole 
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heart, myocardium, lungs, and calculating the second cancer risks for contralateral breast and lungs. 
Statistical significance was established for each compared dosimetric and radiobiological endpoint. 
BECT+VMAT treatment plans were created for nine of the ten patients select for this study. All ten 
patients had VMAT plans created. Six of the nine patients planned with BECT+VMAT and four of the 
ten patients planned with VMAT did not meet the plan acceptance criteria for the PTV goal of V95% ≥ 
95%. However, all of the BECT+VMAT and VMAT treatment plans were deemed clinically acceptable 
by a radiation oncologist.  All nine BECT+VMAT and all ten VMAT patients met the plan acceptance 
criteria that V20Gy < 20% for the lungs and V22.5Gy < 20% for the heart.   
BECT+VMAT showed, with statistical significance, less conformity and less dose homogeneity 
compared to VMAT. No statistically significant difference was exhibited for TCP between 
BECT+VMAT and VMAT. All of the BECT+VMAT patients achieved nearly 100% TCP and six of the 
ten VMAT patients achieved nearly 100% TCP. This was expected because all plans were normalized to 
have 95% PTV volume receive 95% of the prescription dose (47.5 Gy).  
BECT+VMAT was able to reduce, with statistical significance, 𝑉5Gy for the lungs over VMAT. 
On the other hand, BECT+VMAT showed with statistical significance higher 𝑉20Gy than VMAT. Simply 
stated, BECT+VMAT is able to reduced low doses to the lungs but increases high doses to the lungs as 
compared to VMAT. This is probably due to dose spilling of the electron beam to the ipsilateral lung. 
Since the electron beam dose falls off quickly in the low dose area, the contralateral lung has reduced 
dose. van der Laan et al. (2010) studied ten left-sided PMRT patients using a combined electron and 
photon IMRT planning technique and they found comparable mean lung doses as seen in this study. No 
statistically significant difference was seen between BECT+VMAT and VMAT for 𝑁𝑇𝐶𝑃 of the lungs. 
𝑁𝑇𝐶𝑃 of the lungs with radiation pneumonitis grade two or higher as an endpoint was concluded to have 
a mean probability of approximately 2.7% for both techniques. In addition, no statistically significant 
difference was seen between BECT+VMAT and VMAT for 𝑆𝐶𝐶𝑃 of the lungs. 𝑆𝐶𝐶𝑃 of the lungs was 
concluded to have a mean probability of approximately 14.3% for both techniques. 
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BECT+VMAT was unable to reduce the mean dose to the heart as compared to VMAT with 
statistical significance.  In a study conducted by van der Laan et al. (2010) looking at patients using a 
combined electron and photon IMRT technique, similar mean heart doses were observed. However, 
BECT+VMAT was able to reduce, with statistical significance, 𝑉5Gy and 𝑉30Gy for the heart over VMAT. 
This resulted in a statistically significant reduction in 𝑁𝑇𝐶𝑃 of the whole heart for BECT+VMAT plans 
compared to VMAT. The patient averaged predicted risk of cardiac mortality (𝑁𝑇𝐶𝑃) for the whole heart 
was determined to be 0.72±0.56% for VMAT and 0.28±0.28% for BECT+VMAT. Furthermore, the 
patient averaged predicted risk of cardiac mortality (𝑁𝑇𝐶𝑃) for the myocardium was determined to be 
1.14±0.91% for VMAT and 0.43±0.42% for BECT+VMAT. 
Significant reduction in patient average mean dose and 𝑉5Gy of the contralateral breast was 
observed for BECT+VMAT compared to VMAT. The mean contralateral breast dose was in agreement to 
a similar study conducted by van der Laan et al. (2010). In addition, BECT+VMAT was able to reduce 
the contralateral breast 𝑆𝐶𝐶𝑃 by over 50%. 𝑆𝐶𝐶𝑃 values were 3.03±0.88% for VMAT and 1.50±0.50% 
for BECT+VMAT. 
Skin erythema is expected for post-mastectomy chest wall patients since the skin is included in 
the PTV. Dose to the skin should be as close to prescription dose (50 Gy) as possible to sterilize any 
microscopic disease still present. Mean dose to the skin (5 mm shell) was statistically significantly higher 
(50.5 Gy) and just over prescription dose (50 Gy) for BECT+VMAT and was slightly lower (49.3 Gy) 
than the prescription dose for VMAT. Moist desquamation is also a concern with radiotherapy techniques 
for breast cancer and post-mastectomy patients. Perkins et al. (2001) studied a single PMRT patient who 
underwent a BECT technique and determined the patient had brisk erythema and moist desquamation but 
was able to complete treatment without interruption. Chen et al. (2010) has shown that TV-V110% > 5.13% 
is an indicator of radiation induced skin toxicity that results in moist desquamation. 𝑇𝑉 − 𝑉110% for 
BECT+VMAT was significantly higher than VMAT but both techniques had mean values less than 
5.13% so the patients did not show an increased risk of moist desquamation of the skin. 
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In summary, BECT+VMAT achieved comparable dose coverage of the PTV as compared to 
VMAT. In addition, BECT+VMAT significantly lowered risks for whole heart and contralateral breast 
compared to VMAT. However, BECT+VMAT showed comparable risks for the lungs and myocardium 
compared to VMAT. Patients with prior or current cardiopulmonary complications or those at an 
increased risk of cardiovascular disease may benefit from BECT+VMAT. Also, young women with an 
increased risk of radiation-induced cancer of the contralateral breast may benefit from BECT+VMAT.  
4.2 Outcomes of Specific Aim Two 
Specific aim two compared treatment plans and predicted risks of side effects between 
FFFVMAT (6x and 10x) and VMAT plans. This was achieved by creating comprehensive dose 
reconstructions, calculating tumor control probability, determine normal tissue complication probability 
for the whole heart, myocardium, lungs, and calculating the second cancer risks for contralateral breast 
and lungs. Statistical significance was established for each compared dosimetric and radiobiological 
endpoint. Treatment plans for VMAT, FFFVMAT6x, and FFFVMAT10x were created for all ten 
patients. Three of the ten patients planned with FFFVMAT6x, four of the ten patients planned with 
FFFVMAT10x, and four of the ten patients planned with VMAT did not meet the plan acceptance criteria 
for the PTV goal of V95% ≥ 95%. However, all of the FFFVMAT6x, FFFVMAT10x, and VMAT 
treatment plans were deemed clinically acceptable by a radiation oncologist. All ten FFFVMAT6x, 
FFFVMAT10x, and VMAT patients met the plan acceptance criteria that V20Gy < 20% for the lungs and 
V22.5Gy < 20% for the heart. 
FFFVMAT6x and FFFVMAT10x showed, with no statistical significance, similar conformity 
and dose homogeneity compared to VMAT. No statistical significance was shown for TCP for either 
FFFVMAT technique over VMAT. Results from previous studies were in agreement with our outcomes 
for CI, DHI, and TCP for VMAT (Nichols et al., 2014, Wang et al., 2015, Zhang et al., 2015). Six of the 
ten FFFVMAT6x, nine of the ten FFFVMAT10x, and six of the ten VMAT patients achieved nearly 
100% TCP. This was expected because all plans were normalized to have 95% PTV volume receive 95% 
of the prescription dose (47.5 Gy). 
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No statistical significance was seen in the mean lung dose for either FFFVMAT technique over 
VMAT. The mean lung dose reported in this work for VMAT was comparable to previously published 
research (Wang et al. 2015). In fact, both FFFVMAT techniques increased, with statistical significance, 
the 𝑉 5Gy and 𝑉 20Gy compared to VMAT. No statistically significant difference was seen between 
FFFVMAT6x and VMAT or FFFVMAT10x and VMAT for 𝑁𝑇𝐶𝑃 of the lungs. 𝑁𝑇𝐶𝑃 of the lungs with 
radiation pneumonitis grade two or higher as an endpoint was concluded to have a mean probability of 
approximately 3.0% for all techniques. Nichols et al. (2015) determined 𝑁𝑇𝐶𝑃 of the lungs to be 0.3 ± 
0.1% based on 15 VMAT plans; significantly lower than calculated in this study. In addition, no 
statistically significant difference was seen between FFFVMAT6x and VMAT or FFFVMAT10x and 
VMAT for 𝑆𝐶𝐶𝑃  of the lungs. 𝑆𝐶𝐶𝑃  of the lungs was concluded to have a mean probability of 
approximately 13.8% for all techniques. Nichols et al. (2015) found the 𝑆𝐶𝐶𝑃  of the lungs to be 
approximately 5.3% for VMAT. Again, results that were lower than determined by this work. 
No statistically significant change in mean heart dose was observed between FFFVMAT10x and 
VMAT. However, a statistically significant increase in mean heart dose was seen for FFFVMAT6x over 
VMAT with an increased value of 9.9±2.0 Gy vs. 9.0±1.5 Gy, respectively. Zhang et al. (2015) and 
Nichols et al. (2014) both determined a mean heart dose of around 13 Gy for 15 VMAT patients. In 
addition, 𝑉22.5Gy and 𝑉30Gy for the heart was significantly higher for FFFVMAT6x and FFFVMAT10x 
compared to VMAT. 𝑁𝑇𝐶𝑃 of the whole heart and myocardium for FFFVMAT6x vs. VMAT was 
increased with statistical significance. The patient averaged predicted risk of cardiac mortality (𝑁𝑇𝐶𝑃) 
for the whole heart was determined to be 0.72±0.56% for VMAT and 0.94±0.58% for FFFVMAT6x. 
𝑁𝑇𝐶𝑃 values for the whole heart reported here for VMAT are in agreement with values published in the 
literature (Nichols et al., 2014, Wang et al., 2015). The patient averaged predicted risk of cardiac 
mortality (𝑁𝑇𝐶𝑃) for the myocardium was determined to be 1.14±0.91% for VMAT and 1.49±1.0% for 
FFFVMAT6x. No statistical significance was observed in 𝑁𝑇𝐶𝑃 of the whole heart and myocardium for 
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FFFVMAT10x plans compared to VMAT. The 𝑁𝑇𝐶𝑃 of the whole heart and myocardium values were 
approximately 0.8% and 1.3% for both techniques, respectively.  
Significant reduction in patient average mean dose and 𝑉5Gy of the contralateral breast was 
observed for FFFVMAT6x compared to VMAT. No significant difference was seen for FFFVMAT10x 
over VMAT. Nichols et al., (2014), Wang et al., (2015), and Zhang et al. (2015) reported the mean dose 
to the contralateral breast for VMAT as 1.5 Gy, 2.1 Gy, and 1.7 Gy, respectively. All of which were less 
than the mean dose of 3.8 Gy reported in this work. FFFVMAT6x was able to reduce the contralateral 
breast 𝑆𝐶𝐶𝑃. 𝑆𝐶𝐶𝑃 values were 3.03±0.88% for VMAT and 2.55±0.63% for FFFVMAT6x. However, 
FFFVMAT10x was unable to reduce the 𝑆𝐶𝐶𝑃 for the contralateral breast.  
No statistically significant difference was seen for the mean skin dose between either FFFVMAT 
technique and VMAT. All techniques were slightly under prescription dose (50 Gy) with a patient 
averaged mean skin dose of 49.2 Gy. Finally, no significant difference was seen for 𝑇𝑉 − 𝑉110% for any 
VMAT technique and all had mean values less than 5.13% so the patients did not show an increased risk 
of moist desquamation of the skin. 
In summary, FFFVMAT6x and FFFVMAT10x maintained equal dose coverage of the PTV 
compared to VMAT. In addition, FFFVMAT6x significantly lowered the predicted risk of side effects for 
the contralateral breast. However, FFFVMAT6x actually induced higher risks for the whole and 
myocardium but the absolute increase was very minor (~0.22% increase for whole heart and ~0.35% 
increase for myocardium, respectively). Furthermore, FFFVMAT techniques can significantly reduce 
total treatment times. Clinically, young women with increased risk of radiation-induced cancer of the 
contralateral breast may benefit from FFFVMAT6x. 
4.3 Implications and Significance of the Results 
Cardiac toxicity is a serious concern for women undergoing PMRT. Cardiac toxicity has been 
indicated as a primary reason for mortality among breast cancer survivors (Johansson et al., 2002, 
Senkus-Konefka and Jassem, 2007). This work has show with statistical significance that BECT+VMAT 
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technique applied to left-sided PMRT chest wall patients can reduce NTCP for the whole heart. Patients 
with prior or current cardiopulmonary complications or those at an increased risk of cardiovascular 
disease (Weber et al., 2006) may benefit from BECT+VMAT. It was also determined that BECT+VMAT 
can significantly reduce the SCCP for the contralateral breast. This is especially important for young 
patients. Studies have determined that premenopausal women under the age of 40 – 45 years old are at the 
highest risk for second cancers of the contralateral breast after radiation exposure and women over that 
age shown little or no risk of radiation-induced breast cancer (Boice et al., 1992, Travis et al., 2011). It is 
possible that younger patients requiring PMRT may further benefit from BECT+VMAT. 
 This work has determined that patients with more tissue between the distal PTV margin and the 
parietal pleura, thick tissue around the ribs and intercostal space, benefit the most from BECT+VMAT. 
This thick tissue has increased ability to attenuate the electron beam leading to decreased doses of the 
heart and lungs. In addition to further improve the BECT+VMAT technique it may be advantageous to 
pay closer attention to the PTV thickness in the lateral/posterior areas. When this region of the PTV is 
very thick the required electron energy must be increased to achieve optimal dose coverage. Higher 
electron energies result in larger distal dose fall-off regions, increasing lung and heart dose.     
FFFVMAT6x was shown with statistical significance to reduce the contralateral breast SCCP. 
For the same reasons stated previously, FFFVMAT6x may be beneficial to younger patients who are at 
increased risk of radiation-induced cancer of the contralateral breast.  
Furthermore, both FFFVMAT techniques were shown to significantly reduce treatment times for 
PMRT patients. This would implicate FFFVMAT plans could be advantageous for patients who need 
reduced treatment times. This could be people who are unable to remain on the treatment couch for longer 
periods due to discomfort. Reduced treatment times can also be beneficial for breath hold techniques. In 
addition, this work resulted in MU for VMAT in agreement with the literature (Wang et al., 2015, Zhang 
et al., 2015). This would indicate the VMAT plans of this work where of similar complexity as those 
created by other researchers.  
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4.4 Strengths and Limitations 
This study was supported by many strengths: we compared novel advanced PMRT techniques, 
including VMAT, FFFVMAT (6x and 10x), and BECT+VMAT that were not investigated previously in 
the literature and realistic clinical patients were used. Planning was conducted using commissioned data 
for flattening filter free beams for energies 6 MV and 10 MV using a clinical TPS. We conducted detailed 
risk calculations that were used for comparing advanced techniques to the VMAT technique. Each plan 
was radiation oncologist approved and the entire dosimetry team assisted with questions and problems 
encountered when treatment planning. We calculated normal tissue complication probability and second 
cancer complication probability using recent dose response models. Not only was whole heart NTCP 
calculated, we went further by adding the myocardium contour and determining its NTCP based on Zhang 
et al. (2013) work further increasing the robustness of the NTCP outcomes for the heart. We included 
stray radiation dose in our second risk calculations by conducting out-of-field TLD dose measurements 
with an anthropomorphic phantom and corrected the DVHs used in calculating second risks, while most 
previous studies completely ignored stray radiation doses.  
There were also a few limitations to this study. Only ten patients were included for the VMAT 
treatment plans and only nine patients were included for the BECT+VMAT treatment plans. Statistical 
significance and power could be improved by adding more patients to the population. In addition, 
BECT+VMAT is a very labor-intensive technique with respect to treatment planning and delivery. The 
planning process takes many intermediate steps with a significant amount of manual manipulations of the 
treatment planning software like transferring the electron dose distribution into the composite photon 
plan. In addition, the technique requires using a the third party .decimal p.d (.decimal, Inc., Sanford, FL) 
software. The machineable wax bolus also needs to be created off-site and upon receiving needs to have 
addition quality assurance conducted. BECT+VMAT also requires the manufacture of large cerrobend 
blocks that take time to create and are cumbersome to use by radiation therapist.  
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4.5 Future Work 
 Potential future work for this study could be increasing the number of patients. This would 
increase the statistical power of this study. Adding more left-sided PMRT patients, including right-sided 
PMRT patients, and including patients who have immediate breast reconstruction before PMRT can 
provide a clearer picture of who may benefit the most from advanced PMRT techniques and give a better 
understanding of when a certain technique may be more beneficial over another. Including patients who 
have metallic tissue expanders that may perturb the dose distributions could have a significant impact on 
the feasibility of the BECT+VMAT since the high-Z material can negatively affect the electron beam.  
 Another interesting future work would be adding intensity modulated electron therapy (IMET) in 
this study. This technique could potentially reduce the magnitude of any hot and cold spots. This could 
also remove the need for VMAT for the latter technique. IMET could potentially lead to more conformal 
and homogenous dose distributions to the PTV and reduce the low dose bath to OARs.  
 In addition, it would be interesting to study the effect of adding breath hold technique. Patient 
breath holding can increase the distance between the chest wall PTV and the heart further leading to 
decreased heart dose. 
 Another future work would be to measure the total treatment time for all of the VMAT plans 
created for this project. This would increase the confidence that FFFVMAT can significantly reduce 
treatment time over VMAT.   
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Chapter 5 Conclusion  
The results of this study have effectively shown our hypothesis was supported insofar as 
BECT+VMAT maintained equal or better dose coverage than VMAT. The results also support the 
hypothesis that BECT+VMAT can statistically significantly lower the predicted risk of side effects for the 
heart and contralateral breast. However, the hypothesis that BECT+VMAT can significantly reduce the 
predicted risk of side effects to the lungs was not supported. 
In addition, the results of this study have shown our hypothesis was supported that FFFVMAT6x 
can maintain equal or better dose coverage than VMAT. The results also support the hypothesis that 
FFFVMAT6x can statistically significantly lower the predicted risk of side effects for the contralateral 
breast. However, the hypothesis that FFFVMAT6x can significantly reduces the predicted risk of side 
effects to the lungs and heart was not supported.  
Finally, the results of this study have shown our hypothesis was supported that FFFVMAT10x 
can maintain equal or better dose coverage than VMAT. However, the hypothesis that FFFVMAT10x can 
significantly reduces the predicted risk of side effects to the lungs, heart, and contralateral breast was not 
supported. Our study has also shown that FFFVMAT techniques can significantly reduce total treatment 
times.   
This work has shown that BECT+VMAT produces clinically acceptable plans while reducing 
OAR doses. Both FFFVMAT techniques are comparable to VMAT with FFFVMAT6x having slight 
improvements. Even though all VMAT techniques produce more homogenous and conformal dose 
distributions, BECT+VMAT is a viable option for treating post-mastectomy patients possibly leading to 
reduced risks of normal tissue complications. 
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Appendix A: Isodose Distributions and Dose Volume Histograms 
Isodose distributions along with dose volume histograms for each patient within the sample 















Figure A.1 DVH for patient CW1 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 
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Figure A.2 DVH for patient CW1 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 

























Figure A.3 DVH for patient CW1 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 
for FFFVMAT10x (dashed line) and VMAT (solid line). 
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Figure A.4 Isodose distribution for patient CW1 for VMAT (top), FFFVMAT6x (top middle), 

































Figure A.5 DVH for patient CW2 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 
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Figure A.6 DVH for patient CW2 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 

























Figure A.7 DVH for patient CW2 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 
for FFFVMAT10x (dashed line) and VMAT (solid line). 
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Figure A.8 Isodose distribution for patient CW2 for VMAT (top), FFFVMAT6x (top middle), 
































Figure A.9 DVH for patient CW3 comparing PTV (red), lungs (blue), heart (magenta), and breast (green) 
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Figure A.10 DVH for patient CW3 comparing PTV (red), lungs (blue), heart (magenta), and breast 

























Figure A.11 DVH for patient CW3 comparing PTV (red), lungs (blue), heart (magenta), and breast 
(green) for FFFVMAT10x (dashed line) and VMAT (solid line). 
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Figure A.12 Isodose distribution for patient CW3 for VMAT (top), FFFVMAT6x (top middle), 































Figure A.13 DVH for patient CW5 comparing PTV (red), lungs (blue), heart (magenta), and breast 
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Figure A.14 DVH for patient CW5 comparing PTV (red), lungs (blue), heart (magenta), and breast 

























Figure A.15 DVH for patient CW5 comparing PTV (red), lungs (blue), heart (magenta), and breast 
(green) for FFFVMAT10x (dashed line) and VMAT (solid line). 
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Figure A.16 Isodose distribution for patient CW5 for VMAT (top), FFFVMAT6x (top middle), 
































Figure A.17 DVH for patient CW6 comparing PTV (red), lungs (blue), heart (magenta), and breast 
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Figure A.18 DVH for patient CW6 comparing PTV (red), lungs (blue), heart (magenta), and breast 

























Figure A.19 DVH for patient CW6 comparing PTV (red), lungs (blue), heart (magenta), and breast 
(green) for FFFVMAT10x (dashed line) and VMAT (solid line). 
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Figure A.20 Isodose distribution for patient CW6 for VMAT (top), FFFVMAT6x (top middle), 

































Figure A.21 DVH for patient CW7 comparing PTV (red), lungs (blue), heart (magenta), and breast 
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Figure A.22 DVH for patient CW7 comparing PTV (red), lungs (blue), heart (magenta), and breast 

























Figure A.23 DVH for patient CW7 comparing PTV (red), lungs (blue), heart (magenta), and breast 
(green) for FFFVMAT10x (dashed line) and VMAT (solid line). 
- - - - - FFFVMAT6x 
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- - - - - FFFVMAT10x 
















































Figure A.24 Isodose distribution for patient CW7 for VMAT (top), FFFVMAT6x (top middle), 
































Figure A.25 DVH for patient CW8 comparing PTV (red), lungs (blue), heart (magenta), and breast 
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Figure A.26 DVH for patient CW8 comparing PTV (red), lungs (blue), heart (magenta), and breast 

























Figure A.27 DVH for patient CW8 comparing PTV (red), lungs (blue), heart (magenta), and breast 
(green) for FFFVMAT10x (dashed line) and VMAT (solid line). 
- - - - - FFFVMAT6x 
            VMAT 
- - - - - FFFVMAT10x 
















































Figure A.28 Isodose distribution for patient CW8 for VMAT (top), FFFVMAT6x (top middle), 
































Figure A.29 DVH for patient CW9 comparing PTV (red), lungs (blue), heart (magenta), and breast 
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Figure A.30 DVH for patient CW9 comparing PTV (red), lungs (blue), heart (magenta), and breast 

























Figure A.31 DVH for patient CW9 comparing PTV (red), lungs (blue), heart (magenta), and breast 
(green) for FFFVMAT10x (dashed line) and VMAT (solid line). 
- - - - - FFFVMAT6x 
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- - - - - FFFVMAT10x 
















































Figure A.32 Isodose distribution for patient CW9 for VMAT (top), FFFVMAT6x (top middle), 









































Figure A.33 DVH for patient CW10 comparing PTV (red), lungs (blue), heart (magenta), and breast 
























Figure A.34 DVH for patient CW10 comparing PTV (red), lungs (blue), heart (magenta), and breast 
(green) for FFFVMAT10x (dashed line) and VMAT (solid line). 
- - - - - FFFVMAT6x 
            VMAT 
- - - - - FFFVMAT10x 





































Figure A.35 Isodose distribution for patient CW10 for VMAT (top), FFFVMAT6x (middle), and 
















Appendix B: List of Abbreviations 
 AX: Axillary  
 BECT: Bolus Electron Conformal Therapy  
 BECT+VMAT: Bolus Electron Conformal Therapy with Volumetric Modulated Arc Therapy 
 BEV: Beams Eye View 
 CI: Conformity Index 
 DHI: Dose Homogeneity Index 
 FFFVMAT6x: Flattening Filter Free Volumetric Arc Therapy 6 MV 
 FFFVMAT10x: Flattening Filter Free Volumetric Arc Therapy 10 MV 
 fx: Fraction  
 Gy: Gray 
 IMET: Intensity Modulated Electron Therapy  
 IMN: Internal Mammary chain lymph Nodes 
 IMRT: Intensity Modulated Radiation Therapy 
 IMXT: Intensity Modulated X-ray Therapy 
 MU: Monitor Units 
 NS: No Statistical Significance 
 NTCP: Normal Tissue Complication Probability 
 OARs: Organs at Risk 
 PMRT: Post-Mastectomy Radiotherapy 
 PTV: Planning Target Volume 
 ROI: Region Of Interest 
 RTOG: Radiation Therapy Oncology Group 
 Rx: Prescription 
 SC: Superclavicular  
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 SCCP: Second Cancer Complication Probability 
 VMAT: Standard Volumetric Arc Therapy 
 TCP: Tumor Control Probability 
 TPS: Treatment Planning System 
 VMAT: Volumetric Modulated Arc Therapy 
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